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  Conversion of prion protein (PrP) from its normal, cellular isoform, PrPC, to an 
infectious, misfolded, fibrillar isoform, PrPSc, is responsible for various 
neurodegenerative diseases in a variety of mammalian hosts. Although the structure of 
PrPC is well studied, the structure of PrPSc is not known. Obtaining structural information 
on the misfolded isoform of prion may lead to preventative therapies and treatments of 
prion diseases.  In this study, six single-tryptophan mutants of recombinant PrP were 
expressed, purified, and refolded into PrPC or two misfolded isoforms of prion, PrPβ and 
PrPF.  Solvent accessibilities of the six tryptophan residues were probed among the three 
isoforms using various tryptophan fluorescence techniques. For all six mutants, solvent 
accessibility was shown to decrease following conversion to the misfolded isoforms. 
Tryptophan accessibility data was used to evaluate two computational models of PrPSc, 
the β-helix model and the β-spiral model, and was also compared with experimental data 
in literature. Although neither computational model entirely fit the data, the Surewicz 
model of parallel, in-register β-strands comprising residues ~160-220 was in agreement 
with tryptophan accessibilities of residues within this area. However, more structural 
detail of this experimentally-based model is needed before the two data sets can be fully 
compared.  
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CHAPTER 1: INTRODUCTION 
 
 
In the1900s, a group of diseases was discovered that would challenge the way 
scientists view infectious agents.  From the first successful transmission studies and the 
similarities observed among various diseases, to the controversial definition of a prion 
and the long fought struggle for functional and structural data on multiple isoforms, prion 
protein and its related diseases continue to hold great enigma in the scientific community.  
This chapter gives an introduction to the prion protein starting with the history and 
discovery of different prion diseases and the definition of the infectious agent. This 
chapter also gives an overview of the various isoforms of the prion protein (PrP): the 
cellular PrPC, the infectious PrPSc, and the in vitro PrPβ and PrPF. This chapter then 
concludes with a section on structural models of PrPSc and studies focused on elucidating 
the structure of the infectious isoform along with the goal and aims of my thesis as 
related to the theoretical models of PrPSc.   
1-1.  History, Discovery and Definition of Infectious Agent 
 
The history of prion diseases, known also as transmissible spongiform 
encephalopathies (TSEs), starts as early as the 18th century, but the discovery and 
definition of the proteinaceous infectious particle took until 1982 and nearly a century of 
research before being revealed. Because of the multiple TSE diseases and their variability 
between host species and among similar species, the road to discovery was by no means 
fast and straightforward. It took the work of many scientists who first observed 
commonalities in diseases spanning different host species, who developed more advanced 
and more accessible means of research, and who looked beyond the established 
understanding of infectious agents to uncover the unifying etiology of transmissible 
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spongiform encephalopathies.  This section chronicles the journey of various researchers 
attempting to pinpoint the cause of emerging TSE diseases while unearthing 
commonalities, advancing scientific techniques and redefining the way science views 
infectious agents.    
(A) History of TSE Diseases 
Scrapie     Prion disease has origins in the 1730s with the recognition of a disease 
afflicting sheep, given the name scrapie [1, 2]. For reviews on prion see [2-13].  Diseased 
animals exhibited abnormal behavior such as disinterest, disorientation, cessation of food 
intake, loss of coordination in the hindquarters, and scraping or rubbing against fixed 
objects.  The latter behavior lends the name of the disease [13, 14]. A major histological 
abnormality was observed in the appearance of spongiform vacuolation in brain matter of 
infected animals.  The cause of scrapie infection would not be uncovered for many years, 
but the speculation that it was a transmissible illness was suggested in a German 
publication in 1759 stressing the importance of isolating infected sheep from the herd [1] 
and later in 1932 when sheep contracted scrapie after grazing in a field previously 
inhabited by infected sheep [15].  The transmissible nature of this disease was confirmed 
in 1936 when Cuille and Chelle used intraocular injections containing preparations of 
spinal fluid from diseased sheep to infect healthy sheep [16]. They were able to 
reproducibly show sheep-to-sheep scrapie transmissibility with an incubation period of 
14-22 months [8, 14, 16]. While the infectious nature of scrapie had been demonstrated, 
the causative agent was not yet identified, but accidental incidents of transmission 
provided some insight into the nature of this disease.  Publications by Cuille and Chelle 
in 1939 [13, 17] and later by William Gordon in 1946 [18] demonstrated inadvertent 
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infection of healthy sheep from inoculation with a vaccine containing serum from 
scrapie-infected animals.  An important aspect of these accidental transmissions was that 
the vaccines proved infectious even after the typical treatment of formalin and heat, 
which was used to destroy bacterial contaminants [11, 18]. These occurrences along with 
infection of sheep from materials passed through antibacterial filters [9, 14] left scientists 
speculating that the disease was caused by a slow virus exhibiting an unusually long 
incubation time [11, 19, 20]. 
Research with TSE diseases was slow.  Because of the long incubation times and 
low transmissibility in sheep (~25%), it was difficult for scrapie research to be accessible 
to many scientists [14].  In 1959, Pattison successfully infected goats with scrapie using 
brain inoculum from diseased sheep with 100% success [14, 21]. This significantly 
increased research and data collection, as it required fewer animals.  It wasn’t until 1961 
when Chandler showed transmission to mice that the door opened even wider for less 
expensive, shorter, more accessible laboratory experiments on scrapie [22].  
Kuru     In the 1950’s the anthropologists Ronald and Catherine Berndt were the 
first to describe a disease afflicting the Fore people of Papua-New Guinea, called kuru by 
the natives meaning “to shiver” [3].  This disease involved partial paralysis, involuntary 
twitching, a feeling of coldness and the hallmark trait of shivering. The Fore practiced 
ritual cannibalism and would eat the remains of dead relatives as a sign of respect and 
mourning. When kuru was first discovered [23], there was much debate concerning the 
etiology.  Was it an inherited disease, effects from toxic exposure, caused by dietary or 
environmental factors, an infection [9]? Although Carleton Gajdusek was on the forefront 
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of kuru investigation and published the first report in 1957 [24], it took the insight of 
William Hadlow in 1959 for the first major piece to fall into place [9, 11].  
 Hadlow was a veterinary neuropathologist working on scrapie in England when 
his colleague from Rocky Mountain Laboratory in Hamilton, MT mentioned an exhibit at 
the London Wellcome Medical Museum pertaining to a strain of brain disease in the Fore 
people of New Guinea. As Hadlow viewed the exhibit, he was struck by the similarities 
in neuro-histologic pictures of infected brains; the vacuolated neurons and spongiform 
degeneration were much like those in scrapie-infected brains.  Following these 
observations, Hadlow wrote a letter to the Lancet entitled “Kuru and Scrapie” and sent a 
copy to Gajdusek in 1959 strongly suggesting further tests to inoculate kuru in primates 
[3, 9, 19]. 
CJD     Just as kuru and scrapie had been linked by Hadlow, in 1959 
neuropathologist Igor Klatzo published his speculations concerning similarities between 
kuru and another TSE known as Creuztfeldt-Jakob disease (CJD) [9, 11, 25]. Like 
Hadlow, Klatzo was struck by the histological similarities in brains of infected 
individuals.  Creuztfeldt-Jakob disease was first documented in the 1920s by physicians 
Creutzfeldt and Jakob. In these cases, patients developed symptoms of dementia followed 
by rapid death. Further cases of this type followed, and the cause was either left as a 
mystery or described as the result of an unknown agent [26].      
 In 1966, at the prompting of William Hadlow, Gajdusek was successful in 
transmitting kuru to primates by intracerebral inoculation [27].  He then demonstrated the 
successful transmission of CJD to primates in 1968 [28].  Gajdusek’s accomplishment 
was a major step for investigators of TSE diseases, and in 1976 he won a Nobel Prize for 
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“discovering new mechanisms of disease causes and dissemination” [29, 30]. 
Traditionally, transmissibility is required to classify a bona fide prion disease [3].   
GSS and FFI     The first familial TSE disease was diagnosed in 1928. It 
appeared similar to CJD but differed in such aspects as duration of disease and age of 
onset.  This disease, known as Gerstmann-Straussler-Scheinker Syndrome (GSS) and 
named for the founding researchers, originated from an Austrian family in 1928 [31] and 
1936 [32], but its classification as a TSE did not occur until 1981 when Masters showed 
transmission to primates using brain tissue inoculation [33]. Later studies isolated 
mutations in the prion gene responsible for the onset of disease, showing GSS to be a 
caused by genetic factors [7]. In 1989, Hsiao was the first to identify a mutation (P102L) 
genetically linked with GSS [34].   
 Another familial TSE was identified in 1986. An Italian family reported 
symptoms including insomnia, which worsened until the patients were completely unable 
to sleep, leading to death in 1 or 2 years following onset. This disease had reportedly 
been in the wife’s family for over 200 years [9, 35] and was termed fatal familial 
insomnia (FFI). FFI was also classified as a TSE disease after later being shown to be 
transmissible [36, 37]. In 1992, the identification of a mutation in the prion protein 
(D178N) allowed for classification of FFI as a genetically inherited disease [38].  
BSE and vCJD     Although a variety of TSE diseases had emerged in the 1900s, 
the incidence of infection in humans was low and, according to some neurologists, non-
existent.  This quickly changed with the appearance of bovine spongiform 
encephalopathy (BSE) and subsequent disease transmission to humans in the form of 
variant CJD (vCJD). In the 1980s, hundreds of thousands of cows were affected yearly 
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(mostly in Europe), increasing up to nearly 2 million cows in 2007. This outbreak was 
thought to be caused by contaminated feed made from rendered carcasses. It had huge 
repercussions including bans on import and export of beef products and along with the 
slaughtering of infected animals resulted in staggering economic costs [3, 5, 10].  Besides 
the havoc wreaked on the cattle industry, a variant form of CJD (vCJD) was first 
described in 1996; widespread panic concerning humans ingesting contaminated meat 
and contracting vCJD after long incubation periods brought to light the importance of 
TSE research and prevention [13, 39]. Other diseases such as feline spongiform 
encephalopathies, exotic ungulate encephalopathy (EUE), and transmissible mink 
encephalopathy were caused by the outbreak of BSE and the dispersion of contaminated 
beef products to captive animals in zoos and other industries [3, 5].   
Chronic Wasting Disease     Another noteworthy prion disease affecting animals 
is chronic wasting disease (CWD) in elk and mule deer. Manifestations of CWD include 
small growth size, changes in behavior, head tremors and unusual sleepiness. The 
existence of CWD is especially troublesome to hunters as it is present and spreading via 
horizontal transfer among free-range animals in North America [40].  So far, there is no 
evidence supporting the transmission of CWD to humans, but with the experience of BSE 
and transmission across the species barrier causing vCJD, it has been a valid concern [12, 
13].    
(B) History of Prion Discovery and Definition 
Due to the work and insight of several researchers, transmission was shown to be 
a common factor linking seemingly disparate diseases like kuru, scrapie and CJD to a 
common etiology, but the isolation and identification of the causative agent still remained 
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elusive. It was through advancement of scientific techniques and approaches coupled 
with the ability to theorize outside the established scientific dogma that the responsible 
agent was finally discovered. This section highlights some of the advancements in TSE 
investigation that paved the way for scientific discoveries involving the definition of a 
prion and the mechanism of prion propagation.  
History of Prion Discovery     The transmissibility research led to intense efforts 
to identify the causative agent. Studies had shown that scrapie was transmissible even 
after treating the samples with heat, formalin, RNase, and DNase [14, 41]. In 1966, 
Tikvah Alper demonstrated that the infectious agent could also withstand high doses of 
radiation known to destroy the nucleic acid components of other infectious agents [9, 11, 
42, 43]. Studies by Alper showed the minimum molecular weight still possessing 
infectivity was ~200,000 Da, a size known to be too small for a virus or other cellular 
pathogens [43, 44]. These data suggested that the infectious agent might be novel.   
In the forefront of research was another player waiting to make his grand 
entrance. In 1972, Stanley Prusiner, a resident in neurology became interested in TSE 
diseases after one of his patients died from CJD.  Intrigued by the radiation studies of 
Alper, which strongly supported an infectious agent devoid of nucleic acid, Prusiner 
became interested in the structure of the infectious agent and the prospect of a captivating 
research project [45]. Prusiner realized that his best shot to identify the structure of the 
causative agent was to purify the infectious agent from brain homogenates of diseased 
animals [11].  Purification techniques typically involved subjecting brain homogenates to 
differential centrifugation or other fractionation techniques followed by assays of 
infectivity for each fraction by intracerebral inoculation into mice.  Endpoint infectivity 
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assays were performed in which a series of dilutions were inoculated into mice and the 
highest positive dilution was determined after waiting for the animals to become sick. 
Due to the long incubation time for mice and the numbers required for meaningful 
endpoint titration assays, these experiments were difficult to run in parallel and could 
take an entire year for results [11, 46].  
Help arrived in 1975 when successful inoculation of scrapie into Syrian hamsters 
was demonstrated [47]. By developing an incubation time assay in place of the endpoint 
titration assay, the time required for experiments was ~ 70 days vs 360 days for endpoint 
titration assays in mice. Incubation time was defined as the time between inoculation and 
onset of disease symptoms. It became possible with this assay to determine the prion titer 
in the innoculum as there is an inverse relationship between titer and length of incubation 
[48].  This not only significantly shortened the time between experiments, but also the 
development of the incubation time assay significantly decreased the numbers of animals 
needed for experiments [11].    
Successful purification was achieved in 1982 by enriching fractions of Syrian 
hamster brain for scrapie infectivity [46].  The agent found was a 27-30kDa protease-
resistant core of a protein that was called PrPSc (with “Sc” designating the scrapie origin).  
Partial resistance of PrPSc to proteolysis became a tool for sample enrichment and 
characterization.     
Protein-Only Hypothesis     The first enunciation of a protein-only hypothesis 
occurred in 1967 by a mathematician by the name of John Griffith, who published 
modeling studies concerning the infectious agent of scrapie [49]. One of his models 
involved the possibility that the agent could be an aberrant form of a protein that forms 
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conformational templates and replicates following self-association mechanisms [10, 49, 
50]. In this model, disease could arise through spontaneous formation of an aberrant 
protein or it could occur by transmission of a protein template from an exogenous source. 
Griffith’s mathematical logic coupled with the scientific data showing that the infectious 
agent was a protein, paved the way for a new outlook on infectious agents and 
propagation of disease. 
Scrapie infectivity was shown to diminish after adding agents that disrupted 
protein structure by hydrolysis, modification or denaturation, but no decrease in 
infectivity was observed following treatments that alter nucleic acids [44]. Because of 
these and similar studies coupled with the small size of the infectious particle, Prusiner 
thought it appropriate to give this novel agent a name distinguishing it from viruses. The 
word prion was coined and was defined as a proteinaceous infectious particle that lacks a 
nucleic acid component. Prusiner was quick to add that the possibility that a small but 
essential ligand bound to PrPSc could not be eliminated from his purified preparations 
[46]. Prusiner won a Nobel Prize in Medicine in 1997 for pioneering the discovery of an 
entirely new disease-causing agent and the underlying principles of their mode of action 
[51].   
   Following purification and identification of PrPSc came the sequencing of the 
protein in 1985.  cDNA probes confirmed that the prion gene was expressed in healthy 
adult brains as well as diseased brains, and the likely scenario that normal and infectious 
prion differed only in their conformation was as heretical as the protein-only hypothesis. 
Up until that time, conventional dogma was that one gene made one protein with one 
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structure [11].  Logical evidence for a protein-only mechanism of disease had been 
expressed before, however, and was not entirely inconceivable. 
 Emerging scientific evidence continues to confirm the protein-only theory of 
prion disease and propagation. Although the exact mechanism is still not fully 
understood, current models exist that attempt to explain the mechanism of conversion.   
Barring a few variations on a similar theme, the model for prion conversion and 
aggregation involves a protein-misfolding event followed by the autocatalytic conversion 
of normal cellular prion (PrPC) into PrPSc. This begins a chain reaction that results in an 
accumulation of PrPSc. These aggregate to form insoluble fibrils.  PrPC can either 
spontaneously misfold, catalyzing the formation and subsequent aggregation of other 
PrPSc molecules or PrPC can misfold upon interaction with a misfolded PrPSc seed [13]. 
The conversion from PrPC to PrPSc is accompanied by an increase in β-sheet 
secondary structure as measured by CD and FTIR [5, 52, 53].  From his sedimentation 
experiments, Prusiner had observed non-ideal behavior of PrPSc, and attributed this to a 
hydrophobic nature of the scrapie agent [54, 55]. The formation of hydrophobic β-sheets 
explains the potential for fibril and amyloid plaque accumulation, as hydrophobic 
interactions would propagate the aggregation of misfolded monomers. There has been 
conjecture concerning the presence of a cofactor or protein X that assists in the 
misfolding process [56], and this scenario has not yet been ruled out [57] .  In any case, it 
is the autocatalytic mechanism of prion misfolding using PrPC as a substrate that provides 
a self-replicating model for prion propagation and transmissibility.  
Support and Debate Regarding Protein-Only Hypothesis     Although viewed 
by some as heretical, the protein-only hypothesis and mechanism of disease propagation 
10
was backed by many pieces of evidence.  It has been shown that scrapie infectivity 
copurifies with PrPSc, is maintained in samples where no other particle is detected, and 
significantly decreases with agents that disrupt protein structure (urea, guanidine, trypsin, 
hydrolyzing agents) or bind to PrP (anti-PrP antibodies) [58]. Unlike viral diseases, 
procedures targeted to nucleic acids (radiation, nucleases) produce no decrease in 
infectivity, the infectious agent elicits no immune response such as inflammation or 
antigen presentation and no virus has ever been consistently seen in association with the 
disease [7]. 
Supporting genetic evidence for the protein-only hypothesis includes the absence 
of disease and PrPSc propagation in mice devoid of the PrP gene even after inoculation 
with brain homogenate from scrapie infected mice [59]. Genetic studies also show that 
most, if not all, of the familial TSE diseases are associated with mutations in the prion 
gene.  The fact that familial diseases caused by mutation in the prion gene are able to be 
further transmitted adds additional support to the protein-only hypothesis [13, 50].  Also, 
a study by Meyer-Luehmann et al. has provided evidence that Alzheimer’s disease can be 
transmitted in mice via intracerebral injections of amyloid-β containing brain extracts 
from diseased individuals [60]. This provides major support for the protein-only 
hypothesis as it shows the possibility that other amyloid diseases exhibiting abnormal 
protein components and aggregation like Alzheimer’s, type 2 diabetes, and Parkinson’s 
may be rendered infectious in the laboratory setting.   
Arguments concerning the protein-only hypothesis still exist. Based on 
conventional biology, information is encoded in nucleic acid and not proteins. Therefore, 
the existence of strains exhibiting diverse phenotypes in prion diseases has been a strong 
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argument supporting a nucleic acid component.  Scrapie and other TSEs occur in multiple 
strains. Strains are defined by differences in incubation time, the distribution of vacuole 
formation and amyloid deposits in the brain, and clinical symptoms [5, 12, 50].   This 
disparity has been attributed to conformational differences between PrPSc in the various 
strains; the information regarding the phenotypic differences is encoded in the 
conformation of PrPSc, which is replicated as it recruits PrPC substrate.  Studies have 
shown that PrPSc from various strains exhibit different denaturation profiles, sizes of 
proteinase K resistant fragments as well as different glycosylation patterns [5, 61]. The 
mechanistic details regarding how conformational variations give rise to different 
phenotypic properties of disease still remain unknown.   
The most important piece of information that was missing in support of the 
protein-only hypothesis is the generation of infectious prion in the test tube. If prion 
protein is the sole causative agent of disease, then it should be possible to form infectious 
PrPSc from recombinant, normal PrP. While recombinant PrPC can be misfolded to form 
fibrils, infectivity studies with this isoform have been largely unsuccessful. Inoculation of 
fibrils formed in vitro into mice overexpressing the prion protein has been shown to cause 
disease [62], but it is known that animals overexpressing prion can develop disease 
spontaneously [13].    
Perhaps the closest technique to show formation of infectious PrPSc in vitro is the 
use of protein misfolding cyclic amplification or PMCA. PMCA is a technique based on 
work done by Caughey and coworkers [63] and further refined by Soto [64] that is 
analogous to using PCR for DNA amplification. In PMCA, a PrPSc seed is incubated with 
an excess of wild type PrPC and the mixture is incubated and then sonicated in successive 
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rounds. The incubation allows for the formation and aggregation of prion fibrils. 
Sonication methods fragment the fibrils, creating new seeds.   The amount of PrPSc 
created depends on the number of cycles performed while samples containing no PrPSc 
seed do not show amplification of aggregated protein [64].  Requirements for PMCA and 
the retention of infectivity are substrate PrPC and normal, uninfected brain homogenate 
along with a seed of PrPSc. Dilutions studies using PrPSc infected brain homogenate along 
with PrPC for substrate showed continued amplification even when the mixture contained 
no trace of the initial infected brain homogenate [65]. This shows that replication can 
occur in a cell-free system without the presence of the initial seed, providing further 
support for the protein-only hypothesis [66].  To date, infectivity has not been shown 
from assays using pure PrPC substrate without the cellular factors present in brain 
homogenates or by using recombinant PrPC as a substrate. This supports the idea that an 
additional factor is required for pathology of the disease. While the creation of infectivity 
in the test tube has not yet been conclusively attained, with the PMCA assay it should be 
possible to identify factors necessary for the formation of infectious fibrils in vitro [12, 
13].  
1-2. Prion Isoforms 
Prion protein is unusual in that it can exist in multiple, stable conformational 
states called isoforms.  Disease is associated with the conversion of the cellular isoform, 
PrPC into a misfolded, infectious isoform, PrPSc, which is chemically indistinguishable 
from PrPC differing only in conformation [12].  Furthermore, the diverse phenotypes of 
various strains and diseases caused by the same protein are thought to be structurally 
determined. While NMR has elucidated the structure of PrPC, the structure of the 
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misfolded, infectious isoform is not yet known.  This section reviews the structure and 
biology of PrPC along with hypotheses concerning the normal function of this protein in 
the body.  Also contained in this section is information regarding the misfolded isoform 
of PrPSc along with two other stable isoforms used in laboratory settings, the β-
oligomeric isoform, PrPβ and the recombinant fibrillar isoform, PrPF.    
(A) Cellular Prion, PrPC 
Structure and Biology     Before examining the known information and 
questions concerning the disease-causing, infectious isoform of prion, it is important to 
take a look at the normal, cellular prion isoform found in mammalian species [5]. PrPC is 
the cellular isoform of prion found primarily in the nervous system but is also found in 
bone marrow, blood, lymph nodes, and other organs [6].  Human prion is a 253 amino 
acid protein encoded by a gene with a single exon and one open reading frame [5].   A 22 
amino acid leader sequence instructs the targeting of translation into the endoplasmic 
reticulum (ER) where the protein is processed for eventual secretion.  In the ER, the N-
terminal leader sequence is cleaved, a disulfide bond is formed between residues 179 and 
214, N-linked oligosaccharides are added at Asn181 and 197, and a GPI anchor is 
attached after the cleavage of the C-terminal hydrophobic residues [67].  The post-
translationally modified protein then travels through the Golgi where the sugars are 
trimmed and modified. The protein is then transported to the plasma membrane via 
endocytic vesicles.  PrPC is mainly a GPI-linked, extracellular surface protein located in 
lipid rafts, but a small minority of PrPC constitutively cycles to and from endocytic 
compartments mediated by clathrin coated vesicle uptake [67]. In certain cases, prion 
protein can also exist as a transmembrane protein due to disruptions in translocation 
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events [68] or due to protein mutations causing familial prion disease [11].   PrP can be 
mono, di, or unglycosylated, and this variation may be associated with differential 
neuronal distribution and can distinguish various strains of prion disease [69].   Discovery 
of the prion gene, its recombinant expression in E. coli and purification has led to the 
elucidation of PrPC structure through NMR [70] and X-ray crystallography [71] 
techniques.  Recombinant PrP lacks the glycosylation and GPI anchor, but it is accepted 
as an accurate representation of PrPC [72]. Although sequence and other slight variations 
exist, the major structural features of PrPC among multiple species are highly conserved 
and are defined by two domains [6, 70].  NMR structures from Syrian Hamster prion 
show that residues 23-119 comprise a highly unstructured N-terminal domain containing 
multiple copies of an eight-residue repeating sequence P-H-G-G-G-W-G-Q (octarepeat). 
Residues 125-228 define the well-structured, globular, α-helical, C-terminal domain.  
Residues 113-128 comprise a highly conserved alanine-rich hydrophobic cluster that 
lacks regular secondary structure and is quite dynamic [11, 68, 70].  PrPC contains three 
α-helices, Helix A, B, and C, spanning residues 144-156, 172-194, 200-227, respectively, 
and two short, anti-parallel β-strands, S1 and S2 spanning residues 129-131 and 161-163, 
respectively [70] (See Figures 1-1 and 1-2).    
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Figure 1-1.  Depiction of prion sequence and structural elements showing: leader 
sequence that is cleaved prior to secretion, the unstructured, N-terminal domain 
containing the octarepeat sequences, the hydrophobic cluster and the three α-helices (HA, 
HB, HC) and two β-strands (S1 and S2) along with the disulfide bond and two 
glycosylation sites.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-2. Structure of Syrian hamster PrPC amino acids 125-228 from PDB 1B10, 
modified to include a representation of the unstructured N-terminal domain (amino acids 
23-124, gray), the three α-helices A, B, C (red) and both β-strands (blue).  Random coil 
secondary structure and turns are also in gray.   
 
While the presence of PrPSc is diagnostic of prion disease, the exact mechanism of 
toxicity is unknown. Some propose that disease is caused by a gain of toxic function of 
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PrPSc whereby the misfolded prion is responsible for neuronal apoptosis and pathology of 
disease [6]. Others have speculated that the fibrils are formed to protect the cell from a 
smaller, intermediate species responsible for disease, as smaller oligomers have been 
shown to be more toxic to neurons [73, 74]. Discerning the location of conversion to 
PrPSc could illuminate the mechanisms of apoptosis.  One hypothesis is that the low pH 
of the endosomal compartment destabilizes PrPC, allowing for conversion and 
aggregation, as low pH was shown to trigger PrP misfolding in vitro [75, 76]. Other 
speculative locations of conversion include lipid raft domains on the cell surface, and the 
cytosol [77, 78].  Cells overexpressing PrP showed an accumulation of PrPSc in the 
cytosol due to retrograde transport to the ER when proteasome activity was 
dysfunctional.  The direct mechanism of apoptosis is still controversial but the 
downstream pathways of both proteosome impairment and ER stress have been 
implicated [13].   
Evidence exists that would argue the relationship between PrPSc and pathogenesis 
of disease.  It is possible in some brain areas to show strong staining for PrPSc where 
there is no sign of neurodegeneration. Furthermore, transgenic animal models have 
shown that there can be high levels of brain degeneration in the absence of detectable 
PrPSc as well as high levels of PrPSc in animals with no neuropathologies (for review see 
[79]).   Because of this and other data, some propose that a loss of function of PrPC and 
not the buildup of PrPSc could be the cause of pathogenesis. What exact functions and 
mechanisms are involved, however, still remains to be seen.    
Proposed Function of PrPC     Although highly studied, the role of prion protein 
in non-diseased organisms remains unknown. The creation of knockout mice devoid of 
17
the prion gene produced minor defects in electrophysiology and circadian rhythms, but 
no major neurological or behavioral defects were evident.  It was found that prion 
infectivity and propagation does not occur in PrP null mice, but no critical function could 
be assigned due to the lack of phenotypic abnormalities [59]. There have been many 
studies regarding the putative function of PrPC in the brain (for reviews see [3, 6]).   PrPC 
localizes to lipid rafts, which are patches of plasma membrane often enriched in 
sphingolipids, GPI-linked proteins, and tyrosine kinases also thought to be points of 
signal transduction activity [67].  Because of this along with studies showing evidence of 
prion interacting with various signaling molecules, it has been postulated that PrPC may 
play a role in signal transduction and neuroprotection [80-82].   Other potential ligands 
for PrPC have included the anti-apoptotic molecule Bcl-2 [83].  Sequence homology of 
the octapeptide repeats with a domain common to the Bcl-2 anti-apoptotic family along 
with the ability of PrPC to protect human neurons from Bax –induced apoptosis in vitro is 
evidence that PrPC may belong in this family. This protective effect was not observed 
when PrPC had mutations in the octapeptide repeats or mutations associated with 
inherited prion diseases in the C-terminal region [84].   However, the lack of evidence 
supporting PrPC localization to the mitochondria, ER or cytoplasm where Bcl-2 proteins 
normally exist is an argument against this proposed role of PrPC [13]. 
While numerous alternative functions are proposed [80-82, 85-90], a long held 
thought has been that PrP is involved in copper binding and neuronal protection from 
oxidative damage [91, 92]. The octapeptide repeat residues have been shown to bind Cu2+ 
ions at physiological concentrations at neutral pH and show less affinity at lower pH [93, 
94]. Additionally, high concentrations of copper ions have been shown to rapidly 
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stimulate the reversible internalization of PrPC  [95].  These studies suggest a possible 
mechanism of copper binding, transport and release upon entering the more acidic 
endosomal compartments. Over-expression of PrPC has been shown to increase copper 
uptake into cells and PrP null mice were shown to have lower copper content in brain 
membranes than WT mice [96]. Free Cu2+ is cytotoxic and the role of binding free copper 
ions could prevent oxidative damage throughout the brain.  Although there is some 
controversy concerning the role of prion in copper binding and homeostasis, this 
hypothesis is still readily supported. Infected brain tissue was shown to contain 
heightened amounts of free radicals, oxidative damage of protein and disruption of metal 
ion levels [97].  Copper binding to PrPC is shown to change its conformation and interfere 
with the folding of recombinant PrPC. It is believed that the misfolding of PrPC represents 
a loss of function of copper binding resulting in abnormal metal levels and neuronal 
damage [91].  
Many other proposed functions of PrPC including a role in sleep-awake cycles 
[89], memory and behavior [86], immune system activation [85], synaptic plasticity [87], 
neural stem cell biogenesis and development [88], and renewal of stem cells found in 
bone marrow [90].  Although there is much to learn, research shows PrPC to be a multi-
faceted protein able to interact with multiple ligands and cellular molecules, potentially 
producing wide-range consequences on physiology and behavior [6].      
(B) Misfolded Isoforms 
PrPSc     PrPC is monomeric, soluble, and is sensitive to proteinase K digestion. 
Through an unknown mechanism PrPC misfolds into an isoform enriched in β-sheet 
structure and partially resistant to proteinase K digestion.  This infectious isoform, PrPSc, 
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is found in the brains of diseased mammals, is multimeric, insoluble, and aggregates, 
forming fibrils and plaques in the infected cells. PrPSc is stable at slightly acidic to neutral 
pH conditions and can be detected with the binding of several reporter molecules like 
Congo red, Thioflavine T (ThT), 8-Anilino-1- naphthalenesulfonic acid (ANS) and PrPSc 
specific antibodies. ThT and Congo red both bind to amyloid fibrils and ANS interacts 
with hydrophobic β-sheets [98-101].    
PrPβ     Prion can exist in another abnormal but stable isoform that is derived 
from recombinant PrP and is known as the β-oligomeric isoform [98], denoted as PrPβ by 
our laboratory.  This isoform shares similarities with the PrPSc isoform as it is highly 
enriched in β-sheet secondary structure, binds ANS and some antibodies similarly to 
PrPSc (although with less affinity), and is slightly resistant to proteinase K digestion 
although much less so than PrPSc [98-100]. Antibody binding studies showed residues 90-
120 are accessible in PrPβ but are part of the core of PrPSc amyloids and are not 
accessible in the infectious isoform [98].  
In contrast to the insoluble, infectious PrPSc, the oligomeric forms of PrP are 
soluble, spherical aggregates that are stable at acidic pH [98, 101] and do not bind ThT or 
Congo red. Although various sizes of β-enriched oligomeric particles have been found or 
formed from in vivo and in vitro isolation techniques (varying in size from a few 
molecules to ~100 molecules depending on isolation techniques) [73, 102, 103], the 
soluble, recombinant PrPβ isoform produced using our laboratory techniques is an 
octamer [104]. It has been shown that recombinant PrPβ can form amyloid fibrils under 
certain experimental conditions, but is not infectious [98, 101]. However, small β-
enriched aggregates isolated from brain tissue are found to be more infectious and toxic 
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to neuronal cells than the amyloid fibrils [73, 74]. It is under debate whether PrPβ is on 
pathway to the formation of mature fibrils, but because of its similarities to PrPSc and its 
solubility, PrPβ  is ideal for study using spectroscopic techniques.  
PrPF     The other β-sheet enriched isoform that is readily formed with 
recombinant PrP is the fibrillar isoform, PrPF  [99, 105]. This isoform is most similar to 
PrPSc in that it is insoluble, fibrillar, contains high β-sheet content and is stable at slightly 
acidic to neutral pH.  Recombinant fibrils have been found to be mildly infectious in 
transgenic mice overexpressing PrPC [98], but in most other cases they remain non-
infectious when compared to fibrils isolated from brain tissue.  PrPF is structurally similar 
to PrPSc as viewed by infrared spectroscopy (IR) [99] and its binding to ANS, ThT, and 
Congo red along with PrPSc specific antibodies [98, 100]. Though PrPF has enhanced 
resistance to proteinase K digestion, it has a smaller resistant core than PrPSc. While 
proteinase K digestion of the misfolded isoforms creates fragments of slightly variable 
sizes, the main proteinase K resistant core of PrPSc comprises residues 90-231 and is 
shown to maintain infectivity following digestion [11].  Because of the structural and 
physical similarities to PrPSc, PrPF is used to support data collected from PrPβ and to 
represent the conformation of infectious PrPSc.   
1-3. Structural Elucidation of PrPSc 
 The transition from PrPC to PrPSc is accompanied by the slight decrease of α-
helical secondary structure and a significant increase of β-sheet content. Based on IR and 
Circular Dischroism (CD) spectra, PrPSc has ~40% β−sheet secondary structure as 
compared to PrPC having only ~3% [53, 106, 107]. The aggregated, multimeric nature of 
misfolded prion makes it difficult to use traditional methods for structure determination 
21
such as NMR and x-ray crystallography.  Although 2D crystal structures, x-ray 
diffraction and electron microscopy (EM) pictures can give overall structure 
characteristics that confirm the cross β-sheet spine and fibrillar nature of the misfolded 
forms, the atomic-level structural detail is lacking. Elucidating the structure of the 
misfolded prion isoform may allow for the development of drug therapies or early 
detection systems for prion diseases, or illuminate mechanistic details of conversion and 
disease pathology.  Although the structure is not known, there are two predominate 
computational models of PrPSc predicting structural details. Along with computational 
models, several scientific techniques have been utilized to provide structural data.  This 
section describes two theoretical models of PrPSc and then describes structural data 
obtained through various scientific approaches. For most of these studies and for the 
work described in this thesis, a truncated version of PrP (residues 90 – 232) was used, so 
unless specifically defined, all mention of the N-terminus refers to residue 90, not residue 
23 (see Figure 1-1). This section concludes with my hypothesis and specific aims of my 
thesis as related to the two theoretical models of PrPSc.  
(A) Models 
β-Helix Model     Traditional methods of detailed protein structure determination 
involved NMR and X-ray crystallography techniques. To use these methods, the protein 
sample generally must be soluble in solution, be pure and be concentrated without 
aggregation. Because of these requirements, detailed structural elucidation of PrPSc has 
been hampered.  X-ray diffraction has shown that amyloid fibrils from prion and other 
amyloidogenic precursor peptides contain cross β-structures where the β-sheets are 
arranged parallel to the fibril long axis and the β-strands are perpendicular to this axis 
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[108]. Amyloid fibrils from a fungal HET prion was shown by NMR to form a solenoid 
with a triangular hydrophobic core containing cross β-sheet structure [109]. Microscopic 
techniques have given constraints of fibrillar size and morphology for mammalian PrP. 
One EM study observed the formation of fibrillar rods with 69 X 69 Å cross section 
dimensions [110]. Although these data provide a glimpse of the gross morphology of 
PrPSc, they lack the detail necessary for high resolution structural determination.  Using 
these pieces of information as a guide, Govaerts et al published a model of PrPSc structure 
known as the β-helix model [111].  The model was created by searching a database of 
known protein structures for a model that would fit the constraints of the gathered data.  
Specifically, the search criteria for a structure included a cross β-architecture, a diameter 
of <50 Å, and exposed β-sheet edges to allow for the stacking of monomers.  Once the 
potential candidates were identified, the PrP protein sequence was threaded through the 
structures to observe compliance. From these, a parallel, left-handed β-helical structure, 
where the β-strands turn inward and helically wind about an imaginary axis, seemed to 
best fit the data and constraints.  
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A. B. 
Figure 1-3. The Govaerts β-helix model of PrPSc colored by secondary structure where 
α-helices are red, β-strands are blue and random loops, coils in gray. Structure 
coordinates were kindly provided by Govaerts [111].  
 
In this model, residues 90-175 form the β-helices while the C-terminal α-helices 
B and C remain mostly intact as does the disulfide bridge. The formation of this β-helical 
conformation allows for trimeric units that roughly fit the fibril dimensions. The trimers 
have the ability to stack and interact at the tops and bottoms of the β-helical interfaces to 
form a cross β-structure parallel to the long fibril axis [111]. This model agrees with data 
supporting conformational rearrangement in the N-terminus while the two C-terminal α-
helices remain relatively unchanged [112]. 
β−Spiral Model      Mari DeMarco and Valerie Daggett developed the β-spiral 
model for PrPSc structure by using molecular dynamics simulations with the sequence of 
human PrPC (residues 90-231) under conditions of low pH (pH 3.2-4.7) at 25° C [107, 
113, 114].   There is evidence that the misfolding of PrPC may occur in the endosomal 
compartments where the pH is acidic [76, 115].  By mimicking these conditions and 
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using molecular mechanics, they were able to show disruption of salt bridges and tertiary 
structure in the C-terminus of PrPC at low pH, which in turn triggered changes in the N-
terminal region.  In one of the low pH simulations, the N-terminus was seen to form some 
extended structure in the form of β-sheets. The formation of β-strands extending up to 
Helix A and the docking of the new strands to the already existing β-strands in PrPC 
allowed for their packing and stability [114].  This region has been shown to be important 
in the conversion process [116].   
 
 
 
 
 
 
 
A. B. 
Figure 1-4. The Daggett and DeMarco β-Spiral model formed by N-terminal extended 
structure in the form of β-sheets.  (A) shows a trimeric unit (for comparison with the β-
helix model) and (B) shows the monomer-monomer interactions, with interfaces of 
aggregation colored purple and green. Figures are are taken from publications [107, 113]  
(used with permission; (A) copyright 2004 National Academy of Sciences, U.S.A. ). 
 
 
In the β-spiral model, the major structural changes occur in the N-terminus 
whereas all three of the α-helices remain fairly unchanged.  Besides instability and 
increased flexibility caused by the low pH conditions and the loss of long-range salt 
bridges especially in Helix A, the α-helices did not unfold.  This agrees with data 
showing that the C-terminus is not critical for conversion and the large structural changes 
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occur in the N-terminus [3, 114, 117-120].  For example, the formation of disease is seen 
to occur with truncated PrP that lacks Helices A, B, and C whereas the N-terminal and 
hydrophobic region (105-126) are seen to be necessary for conversion and are neurotoxic 
[117, 118, 120]. Another study exhibited the importance of N-terminal residues and the 
hydrophobic segment 113-128 as truncations of this segment did not propagate prions 
[3].  Furthermore, several mutations causing prion disease are found in the N-terminal 
region, and mutation containing a stop codon at 145 or 160 still propagate prion disease 
even though most of the the C-terminus is absent [114, 119]. 
Although contradicting evidence exists concerning the accessibility of the N-
terminus in PrPSc, this region of PrPC clearly undergoes conformational change upon 
conversion to PrPSc.  Antibodies targeting epitopes in the C-terminal region (residues 
225-231) were shown to bind both PrPC and PrPSc, but when antibodies were targeted to 
the N-terminal region (residues 90-120), only epitopes in PrPC and denatured PrPSc were 
reactive (epitopes were not accessible in folded PrPSc) [112]. Baskakov similarly reported 
that residues 90-120 were buried in PrPSc, but antibodies were found to bind these 
residues in PrPβ [98].  There also exist PrPSc-specific antibodies that recognize non-linear 
epitopes in the regions spanning 89-112 and 136-158, which do not bind to PrPC [100].  
Together, these findings implicate that the N-terminal region of PrP undergoes a 
conformational change and plays a role in the conversion process. 
(B) Techniques to Elucidate Structure 
H/D Exchange     A hydrogen-deuterium exchange experiment conducted by the 
Surewicz group shows very strong protection of the amide hydrogens spanning residues 
169-213 in human recombinant PrPF  [121]. This strong protection more than 25 hours 
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after exchange is highly demonstrative of cross β-structure.  While residues 160-213 
were highly protected, residues 90-160 showed only slightly slower deuterium 
incorporation than PrPC, supporting the conclusion that any structure in these residues is 
not involved in the cross-β stacking interactions.  The area of proposed cross β-structure 
in these fibrils corresponds to helix 2 most of helix 3 and the loop between the two 
helices in PrPC [121].   
EPR Spin Labeling     In another paper by Surewicz, recombinant human PrP 
was used for site-directed spin labeling coupled with EPR spectroscopy to locate the 
regions involved in cross β−structure [122]. Upon fibril formation and the associated 
stacking of β-strands, the spin labels on each monomer interact in a distance-dependent 
manner. The EPR spectra provide information on contact sites and the distance and 
packing of monomers.  In this study, the cross β-structure was shown to be in-register 
and stacked parallel to the fiber axis, and was mapped to the C-terminal half of PrP from 
residues 160 to 220. These studies contrast dramatically with both theoretical models of 
PrPSc, as the β-sheets form from Helices B and C of PrPC, contrary to the β-helix and β-
spiral models that show β-sheet structure formation at the N-terminus with most of the α-
helices intact [122].  
Antibody Binding Studies     In another study, fibrils made from full-length 
recombinant mouse prion (23-230) were probed with multiple, specific antibodies 
recognizing different PrP epitopes and conformations. It was seen that under non-
denaturing conditions, epitope 95-105 was solvent accessible whereas epitope 132-156 
was predominantly buried but became partially exposed under slight denaturation [100]. 
Previous studies had shown a proteinase K resistant core of rPrP composed of residues 
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152/153-230 and 162-230 [123]. These residues were thought to compose the stable cross 
β-sheet structures. In this antibody study, epitopes 159-174 and 224-230 were completely 
buried in fibrillar form and full denaturation was required for their accessibility [100].      
Antibody binding studies have been conducted to observe differences in structure 
between PrPC and PrPSc.  A difference in antibody binding of residues 90-113 was 
observed, binding to PrPC but not to PrPSc [98]. Another antibody study showed that there 
was an increase in tyrosine accessibility in PrPSc and found a selective YYR epitope in 
PrPSc that is not accessible in PrPC [124]. These YYR repeats are located at residues 149-
151 and 162-164. and although that study did not identify the exact accessible epitope, 
later studies by Lennon demonstrated that there was a significant increase in tyrosine 
reactivity toward nitration at the 149-151 YYR repeat, pinpointing that segment as the 
accessible epitope [104]. Identifying other regions or residues that are accessible and thus 
specific for one isoform will provide structural clues about the changes that occur 
following conversion.           
(C) Hypothesis and Goals of Research 
There are still many unanswered questions surrounding the conversion of cellular 
protein into the infectious agent that causes disease. Where and how does the conversion 
process take place in the cell, what is the mechanism of apoptosis and disease pathology 
and what is the structure of the infectious isoform? The answers to these questions will 
speed the discovery of therapeutic or preventative agents able to combat prion disease. 
Specifically, determining the structure of PrPSc will enable the advancement of early 
detection systems and clinical screenings to prevent the spread of infectious prion. 
Although gross structural features of fibrils have been observed using microscopy and 
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diffraction techniques, the molecular details of the structure remain to be elucidated. The 
conversion from PrPC to infectious PrPSc is accompanied by changes in conformation as 
seen through antibody binding, IR, CD, hydrogen deuterium exchange and EPR, and 
there are at least two computational models for the structure of PrPSc.  Using structural 
data as it becomes available, it should be possible to validate or provide contrary 
evidence for one or both models.  My research uses tryptophan fluorescence techniques 
with recombinant Syrian hamster PrP (residues 90-232) to quantify the solvent 
accessibility of specific residues in the various recombinant isoforms of prion: PrPC, 
PrPF, and PrPβ. 
My hypothesis is that both the β-helix and β-spiral model are mutually exclusive 
and their differences will be distinguishable by tryptophan fluorescence techniques and 
measurements.  Whether one model is able to entirely represent the data or if they both 
show discrepancies is to be determined. By using tryptophan fluorescence and quenching 
to measure accessibility changes between PrPC and the misfolded isoforms PrPβ and PrPF, 
it will be possible to ascertain if the models represent the data, and to compare the 
acquired tryptophan data with information gathered from other structural studies.  
Aims     The overall aim of my thesis is to probe various isoforms of the prion 
protein using tryptophan fluorescence quenching techniques. Specifically, I will:   
• Measure the tryptophan fluorescence quenching rate constant (kq) for the various 
isoforms (PrPC, PrPβ, PrPF) for several single tryptophan mutants.  The positions 
for Trp placement via mutation are G123W, W145, Y150W, N159W, Y163W 
and Y218W.  The bimolecular quenching rate constant kq will be measured using 
steady-state and time-resolved techniques with acrylamide.  Steady-state 
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quenching kq’s will be correlated with solvent accessible surface area (SASA) 
data and compared with the correlation of the SASA and kq’s from other 
previously reported, naturally occurring, single tryptophan containing proteins 
[125].  
• Estimate solvent accessibility based on kq values for PrPβ and PrPF mutants along 
with the correlation with SASA data.  
• Compare collected fluorescence data with the theoretical models of PrPSc to 
provide support or evidence against one or both models. I will also compare the 
fluorescence data with other published spectroscopic data for further structural 
information.  
• Identify a mutant that exhibits a significant isoform-specific change in solvent 
exposure and/or fluorescence parameters (lifetime). This will be useful for the 
potential development of drug assays or PrPSc detection. 
By monitoring conformational changes between the α-helical rich and β-sheet 
rich isoforms, models of PrPSc can be tested, other structural information can be 
validated, and the information can be used to further develop assays that detect the 
conversion of PrPC to PrPSc.    
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CHAPTER 2: METHODS 
 
 
2-1.  Mutants 
 
(A) Choosing mutants 
Single tryptophan mutants were made to observe changes in solvent accessibility 
at specific residues in PrPC as compared to PrPβ or PrPF. Ideally, positions that exhibited 
the greatest change in solvent accessibility between PrPC and the misfolded isoforms 
were desired.  
The mutants Y163W and Y150W are part of two YYR motifs found in PrP.  
Work done by Cashman and colleagues [1] found that there is increased accessibility of 
one or both of the YYR motifs in PrP isolated from brain homogenates of infected mice 
compared to brain homogenates of non-infected mice.  Specifically, it was reported that 
antibody binding for the YYR epitope occurs in PrPSc but not in PrPC suggesting that at 
least one of these repeats becomes more exposed in the misfolded state.  Since both 
Y163W and Y150W are part of the two YYR motifs, they are of particular interest for 
positions implicated in significant conformational change following conversion to the 
misfolded isoforms. Also, the YYR (residues 149 – 151) motif containing Y150W was 
found to become more sensitive to tyrosine nitration following conversion to PrPβ  [2].  
 Position 218 is a buried residue when looking at the structure of PrPC, but based 
on nitration work previously done in our lab [2], it looks to be more exposed than 
predicted based on visible and calculated solvent accessibility.  One hypothesis was that 
nitration of a neighboring YYD sequence (residues 225-227) slightly changed the 
conformation of PrP and allowed Y218 to become more accessible for nitration.  To look 
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at this position more closely with respect to accessibility and past data from nitration 
work, this mutant was chosen for tryptophan fluorescence quenching studies. 
 Some mutants were chosen based on residues where large differences in solvent 
accessibility were calculated among theoretical models of misfolded prion protein.  Such 
was the case for mutants G123W and N159W.  According to calculations from Valerie 
Daggett and Mari DeMarco [3], G123W and N159W were positions that differed greatly 
in accessibility between two proposed models of misfolded PrP, the β-helix and the β-
spiral model. This would allow for clear distinction between the models when relating 
solvent accessibility results from tryptophan fluorescence quenching measurements in the 
misfolded isoforms.  As seen in Table 2-1, there are clear differences in calculated 
solvent accessibility between the two models for N159W and G123W.          
Summary                  Solvent Exposure 
    PrPC Spiral Beta-helix 
GLY 123 exposed  Exposed (76) buried      (6) 
TRP 145 exposed  Exposed (89) buried     (15) 
ASN 159 buried  buried    (12) exposed (120) 
 
Table 2-1. Positions and their corresponding calculated solvent accessible surface area 
data (SASA) in the β-spiral model and the β-helix model of misfolded PrP are shown. 
Calculated SASA was provided by Mari DeMarco and Valerie Daggett [3]. 
 
W145 is a naturally occurring Trp residue that shows calculated differences in 
solvent accessibility between the two models of misfolded PrP.  Thus, it was a clear 
choice for tryptophan quenching studies. 
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(B) Making Mutations 
The recombinant prion protein construct used in these experiments contained the 
codons for residues 90-231 from golden Syrian hamster prion [4]; this construct lacks 
most of the unstructured N-terminus as well as the C-terminal GPI anchor, and since it is 
expressed in E. coli, the protein product will lack the glycosylation present in eukaryotic 
PrP.  The truncated sequence was used as residues 90-231 have been shown to comprise 
the proteinase K resistant core in PrPSc and are sufficient for fibril formation and 
infectivity [5].  
As described in a previous publication from the McGuirl group [2], the codons for 
residues 90-231 were subcloned from Syrian hamster prion plasmid pHaPrP into 
pET24a+, creating the expression plasmid pET24PrP90. Mutagenesis was performed as 
described below to form the pET24PrP90/W99F template for producing the W145 
variant, and for making pET24PrP90/W99F/W145Y template plasmid containing no 
intrinsic tryptophan residues.  Using the template plasmid, single tryptophan mutants 
were made at selected positions via site-directed mutagenesis using a QuikChange kit 
from Stratagene. Following mutagenesis steps and DpnI digestion to rid the sample of 
methylated parental DNA, the amplified mutant plasmid was transformed into E. coli 
XL-1 blue cells.  The plasmid DNA was isolated from E. coli cells using a QIAprep 
miniprep kit from QIAGEN and submitted to the UM Murdock Sequencing Facility for 
analysis.  The pET24PrP90 mutant plasmids with the desired mutation were transformed 
into E. coli BL21(DE3)-Rosetta cells (Novagen, Inc.) for protein expression. Rosetta 
strains carry the pRARE plasmid that is used to supply tRNAs for mammalian codons 
rarely occurring in E. coli to allow for increased protein expression [6].  The original 
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cloning and some of the mutants were made previously by others in the lab.  Specifically, 
the original cloning and the template pET24PrP90W99F/W145Y, the pET24PrP90W99F 
single mutant plasmid and the pET24PrP90W99F/W145Y/Y218W double mutant 
plasmid were made by Sam J. Chelmo, the pET24PrP90W99F/W145Y/Y163W mutant 
plasmid and the pET24PrP90W99F/W145Y/Y150W plasmid were made by Dr. Hui-
Chun Yeh.  During this project I made the two mutants 
pET24PrP90W99F/W145Y/G123W and pET24PrP90W99F/W145Y/N159W.  
Mutagenesis was performed with a Stratagene QuikChange kit using 20 ng of the 
pET24PrP90W99F/W145Y plasmid template and 50 ng of each primer (N159W or 
G123W forward and reverse primers) with DNA Polymerase and dNTP’s. The N159W 
primer sequences are as followed:  
5’-GAAAACATGAACCGCTACCCTTGGCAAGTGTATTACCGGCCAG for the 
forward primer and  
5’-CTGGCCGGTAATACACTTGCCAAGGGTAGCGGTTCATGTTTTC for the 
reverse primer. The G123W primer sequences are as followed: forward primer sequence 
is 5’-GCGGCAGGGGCCGTGGTGTGGGGCCTTGGTGGCTACATG and the reverse 
sequence is  
5’-CATGTAGCCACCAAGGCCCCACACCACGGCCCCTGCCGC.   After an initial 
denaturation step of 3.5 minutes at 95 °C, PCR cycles were conducted with a denaturing 
temperature of 95 °C for 0.5 minutes, an annealing temperature of 55 °C for 1 minute and 
an extension temperature of 68 °C for 6 min or 1-2 min per kb.  
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2-2. Expression and Purification 
(A) Expression 
BL21(DE3)-Rosetta E.coli cells were transformed with the desired pET24PrP90 
mutant plasmid, selected on LB Kan/Cm plates containing 50 μg/ml kanamycin (Kan) 
and 34 μg/ml chloramphenicol (Cm). Liquid cultures were grown from a single colony at 
37 °C in 2xYT media containing 50 ug/ml kanamycin and 34 ug/ml chloramphenicol 
antibiotics. Cell growth was monitored by optical density readings measured with an 
HP8453A UV-visible spectrophotometer or a Molecular Devices SpectraMax M2e and 
were grown to an OD600 of 1-2 before expression was induced.  To induce expression of 
the prion protein, a lactose analog, isopropyl-β-D-thiogalactoside (IPTG) was added to a 
final concentration of 0.5 mM by adding 1 mL of 0.5 M IPTG per liter of cell culture.  
Cells were grown for an additional 4-5 hours following induction, were spun down and 
were frozen at –20 °C overnight.  Typically 3 liters were grown at a time and cell pellets 
were collected by centrifugation  in an F7S rotor using a Sorvall RC 5B Plus centrifuge at 
5,000 rpm for 20 min. The resulting cell pellets containing prion protein inclusion bodies 
were frozen to induce cell lysis.  
(B) Purification 
PrP was purified using modifications to published procedures [2, 4]. Frozen cells 
were suspended in lysis buffer (50 mM Tris-HCl buffer at pH 7.5 containing 100 μg/mL 
lysozyme) and were shaken at 37 °C for up to 6 hours before being frozen at –20 °C once 
more. After thawing the cells, DNase I was added (10 μg/ml), and the mixture was 
incubated at room temperature for 1.5 hrs before adding 1% Triton X-100 and stirring for 
an additional 10 min.  The cells were then placed on ice for 10 min and were centrifuged; 
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the supernatant was discarded and the inclusion bodies containing the prion protein were 
collected.    
The inclusion bodies containing PrP were purified by repeated resuspension in 50 
mM Tris-HCl pH 7.5 containing 1% Triton X-100 (some purifications used 10 mM 
CHAPS or BugBuster along with Triton X-100) followed by centrifugation.  The 
inclusions bodies were then solubilized in buffer A (8 M urea, 0.1 M potassium 
phosphate pH 8.0) with 50 mg/mL Sigma protease inhibitor cocktail for 1-2 hours. The 
sample was then centrifuged to remove insoluble protein prior to use.  
The supernatant, now containing the solubilized PrP, was collected and subjected 
to ammonium sulfate precipitation by the addition of buffer B (0.1 M potassium 
phosphate pH 8.0) along with NH4SO4 (for a final concentration of 4 M urea 0.1 M 
potassium phosphate, 1 M NH4SO4, 25 % ammonium sulfate saturation) while gently 
stirring.  After being placed on ice for 30 min, the suspension was centrifuged and the 
precipitated protein was suspended in buffer A while the supernatant was saved for 
further NH4SO4 additions and precipitations.  Further additions to 35 % or 70 % NH4SO4 
saturation resulted in a sample with less protein contamination (more pure pellets of PrP) 
although the nucleic acid component increased (as judged by SDS/PAGE and the 
A280/A260 ratios). The suspended protein pellet, now unfolded in buffer A, was further 
purified using a nickel ion affinity column.  The protein was batch bound to 50 ml Ni 
(II)-Chelating Sepharose resin (GE Healthcare) prepared in buffer A, was poured into a 
5cm diameter column and was then washed with buffer A until the A280 reached < 0.03.  
A 2 L linear gradient from buffer A to buffer B was run to refold the protein on the 
column, and the protein was then eluted with 60 mM imidazole in buffer B. Some 
44
mutants were particularly difficult to elute with imidazole and had to be eluted using 
buffer A and then refolded by another process.   
The purity of the eluted protein was tested using SDS/PAGE analysis on a 
Pharmacia PhastSystem (GE Healthcare) using 8-25 % polyacrylamide gels and 
Coomassie Blue staining.  The protein sample was mixed with a 2XTB buffer containing 
20 mM Tris-HCl, 2 mM EDTA, 5% SDS, 10% β-mercaptoethanol and bromophenyl blue 
at pH 8 buffer and boiled at 99 °C for at least 5 min before adding the samples to the gel.  
BioRad broad range standards were used for mass determination.           
 If the samples contained any contaminant protein as seen in the acrylamide gel, 
further purification was necessary and HIC (hydrophobic interaction chromatography) 
was utilized on an AKTA FPLC (Amersham Biosciences).  About 10 mg of protein was 
loaded onto a HI-Prep Phenyl Sepharose 16/10 column (GE Healthcare) in 4 M urea, 1 M 
NH4SO4, 0.1 M potassium phosphate at pH 8.0 and a gradient was run from 1 M to 0 M 
NH4SO4 in 25 mM Tris-HCl, 4 M urea at pH 8.0.  Protein usually eluted from the column 
between 0.4 to 0.5 M NH4SO4. If the protein was sufficiently pure (as judged by 
SDS/PAGE), it was then concentrated in 6 M guanidine hydrochloride for refolding and 
isoform conversion.  
(C) Alternate Purification Techniques 
 While some of the purification was achieved using the protocol outlined above, a 
few mutants were more difficult to purify than others, and the procedure was adjusted for 
a greater and timelier yield.  For some of the mutants, elution off the nickel column could 
not be achieved using 60 mM imidazole and buffer B, so buffer A + imidazole had to be 
used to unfold the protein and elute it.  The refolding process on the column seemed to be 
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problematic for some mutants, so the procedure was adjusted:  before the nickel column, 
solublized samples were refolded by dialysis into buffer B, any insoluble protein was 
removed by centrifugation, and the supernatant was then batch bound to the Ni (II)-
Chelating Sepharose resin.  The column was washed with buffer B until the A280 was 
<0.03 and the protein could be eluted with 60 mM imidazole in buffer B.      
If the protein had could not be purified by HIC or still had contamination 
following HIC purification, the protein was concentrated into 6 M guanidine 
hydrochloride, 10 mM potassium phosphate at pH 8.0 and passed through a 30 kDa 
MWCO membrane in an Amicon stirred cell.  To achieve this, the volume was reduced to 
a few milliliters, more 6 M guanidine solution was added and this process was repeated 
3-4 times to ensure that the majority of PrP (MW ~16 kDa) had passed through the 
membrane. Following concentration of the flowthrough fraction, the sample was dialyzed 
into 10 mM Na Acetate (NaOAc) at pH 5.5 and then the purity was determined via 
SDS/PAGE analysis.   
2-3. Conversion/Refolding to the Three Isoforms 
Pure protein was stored at a concentration of 120 μM in 6 M guanidine 
hydrochloride, 10 mM potassium phosphate at pH 8.0 at 4 °C or –20 °C until being 
refolded into PrPC or converted to PrPβ or PrPF.   Refolding of denatured protein into 
PrPC was achieved by dialysis into 10 mM NaOAcbuffer at pH 5.5 and samples were 
centrifuged before proceeding with data collection.    
 Conversion to PrPβ was achieved by altering a method published by Baskakov et 
al [5]. Using purified protein in the storage conditions above, a 6-fold dilution was 
performed using 1 part protein and 5 parts beta conversion buffer (3.6 M urea, 160 mM 
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NaCl, 60 mM NaOAc at pH 3.7). The conversion solution was stored at 37 °C overnight 
and was dialyzed the next morning into 10 mM NaOAc buffer at pH 5.5 before being 
centrifuged and used in data collection.   
 Conversion to PrPF started with refolding protein into PrPC by dialyzing into 15 
mM potassium phosphate buffer at pH 6.5. The refolded sample was then centrifuged and 
the supernatant mixed with fibril conversion buffer (4.8 M urea, 2 M guanidine 
hydrochloride, 60 mM potassium phosphate at pH 6.5).  One part conversion buffer was 
added to three parts protein and the sample was then concentrated in an Amicon stirred 
cell to a concentration of 1.5 mg/mL.  The concentrated protein was then placed in a Lab-
Line Instruments Titer Plate shaker at a shaking setting of 5 for 16-24 hours at 37 °C.  
The insoluble fibrils were then twice centrifuged at 7000-10,000 rpm for 10 min in a 
microcentrifuge and washed with 15 mM potassium phosphate buffer at pH 6.5. The 
precipitate was pipetted gently to form a suspension; flicking of the eppendorf tube was 
allowed, but vortexing destroyed the fibrils, so harsh treatment was avoided during 
handling. 
2-4. Verification 
 Following purification procedures, the final purity of the protein sample was 
assessed using SDS/PAGE as described in the purification section above.  Protein 
preparations yielded 10-20 mg of highly pure protein as seen in Figure 2-1. 
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Figure 2-1. SDS/PAGE of different mutant protein samples for purity determination 
along with a BioRad broad range standard (S). PrP90 is ~16,000 Da. 
 
Proper conversion to PrPC and PrPβ was verified by using circular dichroism 
(CD), a technique that reports on protein secondary structure.  Measurements were taken 
in a 0.1 cm path cuvette with 8-20 μM PrPC or PrPβ scanning from 190-300 nm at 200 
nm/min using a Jasco 810 spectrophotometer. Measurements were recorded using 5-10 
accumulations at 20-25 ºC using a bandwidth of 2 nm, a response time of 1 second and a 
data pitch of 1 nm.  
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Figure 2-2. Representative CD spectra of N159W PrPC and PrPβ data exhibiting typical 
α-helical or β-sheet spectral characteristics [7]. PrPC is composed mostly of α-helical 
secondary structure and exhibits two minima around 209 and 222 nm while PrPβ is 
composed mainly of β-sheets and has one minimum around 216 nm.  
 
  
CD spectral data was converted to mean residue elipticity (MRE) on the y-axis for 
each sample. Mean residue elipticity [θ] is calculated and then applied to the spectra by 
the equation below. 
 [θ] =1/(10npc)    Equation 2-1 
giving units in degrees cm2 dmol-1  residue -1,  where n is # of residues in the protein, p is 
the pathlength of the cuvette in centimeters and c is concentration of the protein sample 
in μM. 
To determine the MRE, the concentration of converted PrP was needed. Samples 
were unfolded by dilution with a 6.7 M guanidine hydrochloride stock to achieve a final 
concentration of 6.0 M guanidine hydrochloride 0.01 M potassium phosphate pH 7.4. The 
protein concentrations were determined using their absorbance at 280 nm. Extinction 
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coefficients were determined using the ProtParam tool on the Expasy website 
(expasy.org) which calculates protein extinction coefficients using the Edelhoch method 
based on the number of tryptophan, tyrosine, and cysteine residues and their 
corresponding exctinction coefficients determined by Pace et al. [8].  The extinction 
coefficient for single Trp prion protein mutants were similar and were calculated as  
~22,000 M-1cm-1 at 280 nm measured in water. To determine the concentration of the 
fibrillar samples, the protein was diluted into the same guanidine hydrochloride stock 
solution to a final concentration of 6 M guanidine hydrochloride and the fibrils were 
allowed to denature and dissolve for ~30 min before measurements were taken.   The UV 
spectra were taken in a 1 cm pathlength UV cuvette using a UV-visible HP8453A 
photodiode array spectrophotometer.   
 To verify that the mutations introduced in the prion protein did not disrupt the 
conformational stability of PrPC, thermal denaturation profiless were measured via CD. 
The Tm (temperature at which 50% of the secondary structure has disappeared) values 
were obtained and compared with that of WT PrP90. The Tm values for all the mutant 
PrPs were close to WTPrP90 and the unfolding curves appeared similar in shape and 
were consistent with simple two state folding. 
Proper conversion to PrPF was verified using a ThT (thioflavin T) assay [9] and 
electron microscopy imaging techniques.  For the ThT assay, fibrils were diluted into a 5 
mM NaOAc buffer at pH 5.5 containing 10 μM ThT to a final concentration of ~0.3-0.5 
μM protein. The fluorescence emission spectrum (450 – 600 nm) of the resulting 
suspension was measured using an excitation wavelength of 445 nm using a Jasco 810 
CD spectrophotometer equipped with a scanning fluorescence detector. ThT binds to 
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amyloid fibrils, which enhances and shifts its fluorescence emission spectrum (see Figure 
2-3). In contrast, ThT does not bind to PrPC or PrPβ and so the ThT fluorescence 
spectrum does not change from that of the dye alone. 
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Figure 2-3. The fluorescence emission spectra of 10 μM ThT in 5 mM NaOAc buffer pH 
5.5 with and without fibrillar protein. The emission of ThT is much enhanced by the 
presence of 0.5 μM fibrils.    
 
 
Electron microscope images were taken at the UM EMtrix facility using the 
following protocol: 5 μl of fibrils suspended in buffer to a final concentration of 20-100 
μM monomer were bound to Formvar carbon coated specimen grids for 1 hour and then 
washed with water and dyed with uranyl acetate for 30 seconds before being washed 
again with water and dried.  Following binding of the protein on the grids, the images 
were viewed and magnified using a Hitachi H-7100 TEM (transmission electron 
microscopy) instrument and pictures and grids were saved for later usage or viewing. The 
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samples were viewed and proper fibril formation was verified by distinguishing between 
fibrillar structures and globs of precipitate (see Figure 2-4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-4. PrP N159W fibrils at 70,000X magnification (Bar =100 nm).  
 
 
 
52
2-5. Tryptophan Fluorescence Data Collection and Experimentation 
Steady state data were collected at 20 °C on a Jasco 810 CD spectrophotometer 
equipped with a scanning fluorescence detector using 8-20 μM protein in 10 mM NaOAc 
buffer pH 5.5.  Measurements were taken in either a 1 cm or 0.4 cm far-UV quartz 
cuvette (Nova biotech). The sample was excited at 295 nm and the emission was 
recorded from 300-500 nm.  Steady state quenching was accomplished by adding aliquots 
of buffered 5 M acrylamide to the sample so that each addition increased the quencher 
concentration by ~0.05 M, up to a final acrylamide concentration of 0.5 M. Fluorescence 
measurements were performed with a response time of 0.25 sec, a sensitivity of 500 V, a 
data pitch of 1 nm, an excitation bandwidth of 5 nm and an emission bandwidth of 10 
nm. 
 The majority of the lifetime measurements were taken at Fluorescence 
Innovations Inc., in Bozeman, MT using a prototype ultraviolet fluorescence lifetime 
spectrometer.  Florescence measurements were recorded at 20° C and the sample 
temperature was controlled with a four-cuvette turret from Quantum Northwest 
(Spokane, WA). The sample concentration was 8-20 μM, was held in either a 1 cm or 0.4 
cm far-UV quartz cuvette (Nova biotech) and was excited at 292-294 nm using a compact 
frequency-doubled dye laser having 200 μJ energy per pulse, 1000 Hz pulse repetition 
frequency, and 0.5 ns pulse duration. The fluorescence was detected using a Varian Cary 
Eclipse spectrofluorimeter modified with a Hamamatsu R-7400 photomultiplier tube 
(PMT). The PMT was biased at 400-500 V for the various experiments. 
 Time-domain fluorescence data were recorded using a proprietary transient 
digitizer that generates a decay curve for each laser pulse, employs an analog memory 
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and samples at 1 gigasample/sec. The effective sampling rate is increased to every 200 ps 
via 5X interleaving. Each fluorescence decay spectra was averaged over 1000 laster 
shots. Fluoresence data were recorded between 300 and 400 nm for every quencher 
concentration. As with steady-state measurements, a buffered solution of 5 M acrylamide 
was titrated into the sample at 0.05 M increments to a final concentration of 0.5 M 
acrylamide.  Lifetimes of N-acetyl-tryptophanamide (NATA) and p-terphenyl (PTP) were 
measured to derive the instrument response function (IRF) for later data analysis (see 
following section).   
  One trial of lifetime measurements was also performed at UM in The laboratory 
of Dr. JB Alexander (Sandy) Ross using time-correlated single-photon counting (TCSPC) 
with a FLASC 1000 sample chamber (Quantum Northwest, Liberty Lake, WA). Samples 
were excited at 295 nm using a frequency-doubled ps Mira 900 Ti:Sapphire laser 
(Coherent, Santa Clara, CA) and magic angle polarization. The emission was recorded at 
350 nm using the TimeHarp 200 PCI board (PicoQuant, Berlin) until at least 8 X 103 
counts were obtained at the maximum of the decay curve.  Acrylamide was added in 0.1 
M increments up to 0.4 M acrylamide total. The fluorescence decay spectra were 
recorded at 20 °C.  
2-6.  Data Analysis and Modification 
Steady-state fluorescence spectra were analyzed using Origin software or Jasco 
800 windows spectral analysis. Baselines were corrected through editing options and 
volume increases were accounted by normalizing the fluorescence intensities to the initial 
concentrations of protein.  The intensity and λmax (wavelength at maximum fluorescence 
intensity) were extracted and used for further analysis.  
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The data from lifetime measurements were fit using the following process. 
 I(t)= ∑αi exp (-t/τi),   Equation 2-2  
Equation 2-2, where αi is the amplitude of the exponential with lifetime τi, was 
convoluted with the instrument response function (IRF) and the resulting function was 
compared with the data [10].   The αi and τi values were varied using Excel’s Solver 
program and the fit to the data was evaluated using a least-squared analysis. Unless a 
sufficient improvement in χ2 values was obtained by adding another lifetime component 
(χ2 decrease by half), the simplest model was assumed to be the best analysis and the 
τ values (lifetimes or decay times) were then determined. In the cases where more than 
one lifetime was observed, a weighted τ value was calculated using Equation 2-3. 
 <τ> =(α1τ12+ α2τ22)/(α1τ1+α2τ2).  Equation 2-3 
 Fluorescence intensity or lifetime quenching (taken at the λmax of the 
corresponding steady-state spectrum) was plotted using the Stern-Volmer equation. 
  F0/F = τ0/τ = kq(τ0)[Q] + 1   Equation 2-4   
(where F0 is fluorescence in the absence of quencher and F is fluorescence with the given 
quencher concentration, [Q] is quencher concentration and τ0 is the fluorescence lifetime 
of the protein in the absence of quencher).  From the Stern-Volmer plot and the lifetime 
value τ0, the kq or the bi-molecular quenching constant was determined [10].  To correct 
for the presence of static quenching in steady-state measurements and to compare our 
steady-state kq values to published kq values [11] of other single tryptophan-containing 
proteins, the curves were fit, when applicable, to a modified Stern-Volmer equation 
taking into account the static component. 
 F0/F eV[Q] = 1+ KSV[Q]   Equation 2-5   
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where KSV =kqτ0  is the dynamic quenching component and V is the static quenching 
component defined by some as the sphere of action [10]. By plotting F0/F exp(V[Q]) vs 
[Q] and varying V until the best fit line is achieved, it is possible to derive a more 
accurate diffusion-limited rate constant in the presence of static quenching.  It is 
important to note that not all steady-state quenching curves could be fit to the above 
equation as the fit to a straight line could not be improved by adding the static component 
(V).  
To further check the correlation between solvent accessibility and kq values, the 
NMR structure of PrPC obtained from the protein data bank (ID# 1B10, structure no. 4, 
containing residues 109-219) [12, 13] were modified to reflect the sequence of the single-
tryptophan mutants; these were then energy-minimized using Sybyl_7.3 or 8.0.  Energy 
minimizations were performed using the Powell Method Gradient at 0.05  kcal/Å mol. 
The solvent accessible surface area (SASA) of the tryptophan was measured using 
MOLMOL calculations and the exposure of the entire residue (including backbone) was 
recorded and could be compared to the kq results obtained for PrPC. 
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CHAPTER 3: FLUORESCENCE MEASUREMENTS AND RESULTS 
 
The purpose of this project is to probe changes in conformation among the 
various isoforms (PrPC, PrPβ and PrPF) using tryptophan fluorescence measurements. 
Both steady-state and time-resolved fluorescence measurements were used and the 
reasons for using both are outlined here.  Steady-state spectrum measurements require 
simple instrumentation and analysis, providing an accessible method for measuring 
tryptophan fluorescence changes. To quantify the accessibility of the tryptophan in each 
of the isoforms, steady-state measurements were coupled with fluorescence quenching 
using acrylamide and the kq value (quenching rate constant) was determined. Steady-state 
quenching measurements can be complicated by the presence of static quenching and 
determination of the diffusion-controlled kq can prove difficult.  Besides supplying the 
lifetime (τ0) necessary for kq determination, time-resolved measurements were taken and 
coupled with acrylamide quenching to directly provide a diffusion-controlled kq for each 
sample, as these measurements are not influenced by static quenching mechanisms.   
 The purpose of this chapter is to introduce each type of fluorescence 
measurement and show the results. This chapter ends with a section on kq determination 
and a brief discussion of the results.         
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3-1. Steady-State Measurements 
(A) Introduction to Steady-State Measurements 
                      Tryptophan 
 
 
 
 
 
 
 
 
 
 
Figure 3-1.  Jablonksi diagram showing energy states of a molecule. If a molecule in the 
ground state (S0) absorbs a photon with energy equal to the energy difference between the 
ground state and excited state (S1), it will transition to the excited state.  The molecule 
comes to rest within the lowest energy level of the excited state.  An electron’s return to 
ground state can be accompanied by an emission of a photon whose energy is equal to hν 
(Planck’s constant times frequency). Right corner inset showing tryptophan molecule 
with an arrow representing the dominant dipole in the excited state.  
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The relationship between the absorption and emission of photons can be depicted 
using a Jablonski diagram (Figure 3-1).  When a molecule in its ground state (S0) absorbs 
light of a particular energy, a transition occurs to the first excited electronic state (S1) 
where the molecule rapidly relaxes to the lowest vibrational level of S1.  During the 
return to the ground state, the molecule can lose energy in the form of vibration or heat or 
emit a photon (energy equal to hν) in a process known as fluorescence.  While some 
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information regarding the environment of a fluorophore can be derived from the 
absorption spectrum of a molecule, the fluorescence spectrum is generally a much more 
sensitive probe for understanding molecular interaction and conformations.  
For steady-state fluorescence measurements, the sample is excited with a 
continuous beam of light and the emission spectrum is recorded [1]. Steady-state 
fluorescence can be used to derive the quantum yield--the number of photons emitted vs. 
the number of photons absorbed, which is given in Equation 3-1.  
 Ф= kr/(kr + knr)   Equation 3-1. 
In Equation 3-1  kr is the rate of radiative decay processes (fluorescence) and knr is the 
rate of all the other processes that contribute to non-radiative decay (nonfluorescence due 
to nearby quenching molecules; solvent, nearby polar residues or the amide backbone 
etc…[1, 2].   Due to the ability of the indole ring to transfer electrons in the excited state, 
tryptophan fluorescence is highly sensitive to changes in the surrounding environment 
and is commonly used to report changes in conformation or binding events in proteins 
[1].   Tryptophan has a larger dipole moment in the excited state than the ground state 
(Figure 3-1); this causes water molecules to orient themselves around the dipole, stabilize 
the excited state and produce a lower energy of emission. This phenomenon is referred to 
as solvent relaxation and occurs at timescales near 10-10 s, whereas the lifetime of 
tryptophan fluorescence lasts for 10-9 s, so the emission spectrum reflects the solvent 
relaxed state (See Figure 3-1) [1].  The more exposed a tryptophan is to solvent, the more 
solvent relaxation occurs, which causes a lower energy (longer wavelength) of emission. 
Fully exposed tryptophan emits at a λmax (wavelength at intensity maximum) around 350 
nm in aqueous solution.   A blue shift in emission along with an increase in intensity 
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(discussed in more detail in the next section) can indicate a decrease in solvent exposure, 
which in a protein correlates with a more buried residue.  It has been shown that there is a 
strong correlation between the λmax of tryptophan emission and its accessibility to 
exogenous quenchers as determined by kq value [1, 3].  
(B) Steady-State Results 
As seen in Figures 3-2 and 3-3, the spectra of mutants in the 3 different isoforms 
exhibit shifts in intensity and/or wavelength. 
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Figure 3-2. Representative steady-state spectra for Y150W and G123W mutants showing 
intensity vs. wavelength for the three different isoforms PrPC,  PrPβ, and PrPF. All spectra 
normalized to 20 μM concentration.  Spectral overlays for the other mutants can be found 
in the Appendix (Figure A-1).      
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Figure 3-3 (A-C). Representative steady-state spectra overlayed for all the mutants of a 
particular isoform at 20 μM concentration (A) PrPC; (B) PrPβ; (C) PrPF. Y150W ─   
N159W─   G123W ─  W145 ─  Y163W ─   Y218W ─  
 
 
While mutants in the PrPC isoform exhibit a wide range of λmax values (Figure 3-
3A), mutants in the PrPβ and PrPF isoforms similarly show more consistency in their λmax 
values (Figure 3-3, B and C).  Table 3-1 shows all the λmax and intensity values for the 
mutants in the three isoforms for direct comparison.  
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(nm) 
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G123W 353  0.28 347  0.27 339  0.4 
  W145 351  0.10 347 0.17 344  0.21 
Y150W 336  0.62 344  0.21 343  0.29 
N159W 352  0.38 344  0.23 343  0.18 
Y163W 336  0.06 345  0.17 343 0.22 
Y218W 334  0.04 348  0.12 343  0.18 
 
Table 3-1. Representative λmax and intensity values from the steady-state spectra of the 
six mutants in the three isoforms. All intensities are normalized to 20 μM concentration. 
 
For the PrPC isoform, G123W, W145 and N159W show λmax values between 351 
and 353 nm, indicating exposed tryptophan, while Y150W, Y163W and Y218W all show 
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significant blue shifts in emission with λmax around 334-336 nm, which indicates the 
tryptophan is more buried than in the first three mutants. These results are supported by 
MOLMOL [4] calculated solvent accessible surface areas (SASA) for tryptophan 
residues in the PrPC structure, which predicts that  mutants Y150W, Y163W, and Y218W 
have ~3%, 5%, and 10% tryptophan exposure, respectively. In contrast, mutants G123W 
and W145 have ~69% and 50% exposure, respectively.  N159W has 23% accessibility as 
determined by MOLMOL calculations, but has a λmax at 352 nm, which would 
correspond to a much more exposed residue. Thus, λmax values alone may be insufficient 
to accurately assign solvent exposure to a tryptophan molecule within a protein. 
As seen for PrPβ and PrPF, shifts in intensity and λmax can be observed and used to 
predict changes in accessibility of the Trp compared to PrPC. For G123W, there is a blue 
shift in λmax for PrPβ and PrPF and the intensity significantly increases in PrPF, indicating 
the Trp becomes more buried upon conversion. This pattern can also be seen for W145.  
In Y150W, there is a red shift in λmax and a decrease in intensity indicating a more 
exposed residue in PrPβ and PrPF. For the other mutants, however, there are some 
seemingly conflicting observations. For Y163W and Y218W, there is an increase in 
intensity for PrPβ and PrPF indicating a more buried Trp, but the wavelength of emission 
shifts to the red indicating a more exposed residue. For N159W, there is a decrease in 
intensity indicating more exposure, but the blue shift in λmax indicates a more buried 
residue. Because observations in spectral shifts and intensities are influenced by factors 
besides solvent exposure, another approach is needed to measure changes in tryptophan 
exposure among the three isoforms.   
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3-2. Steady-State Quenching Measurements 
(A) Introduction to Steady-State Quenching 
 
 Although it would be convenient to directly correlate shifts in intensity and 
emission to changes in solvent exposure, other environmental factors influence 
tryptophan fluorescence emission as well. Due to the ability of indole to transfer electrons 
in the excited state, factors such as nearby histidine, phenylalanine, or tyrosine residues 
along with amino acids having ionic side chains, polar residues, the peptide backbone, or 
disulfide bonds can influence the fluorescence emission [1].  Anything that acts upon the 
dipole moment of the excited tryptophan including solvent molecules can cause shifts in 
λmax and intensity.  Thus, to more accurately quantify the accessibility of tryptophan to 
solvent, a molecule that diffuses to the fluorophore and quenches the fluorescence 
emission is titrated and changes in fluorescence are measured. By measuring the 
fluorescence as a function of quencher concentration, one can determine the accessibility 
of the quencher to the fluorophore and by analysis determine the solvent 
accessibility/surface exposure of the fluorophore. A Stern-Volmer plot is then 
determined, given by the equation below. 
F0/F= 1+ KSV [Q]=1+kqτ0[Q]   Equation 3-2 
KSV is the Stern-Volmer constant, kq is the bimolecular quenching rate constant, and F0 
and τ0 are the fluorescence intensity at λmax and the lifetime in the absence of quencher, 
respectively.  The Stern-Volmer constant can indicate exposure to quencher, since the 
larger the slope, the more quenching has occurred. However, to fully quantify the 
efficiency of quenching and thus the accessibility of the fluorophore to solvent, kq values 
are calculated and compared. The bimolecular quenching rate constant defines the 
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diffusion-controlled or dynamic rate of quenching over the lifetime of the fluorophore.  
The faster and more efficient the rate of quenching, the more access the quencher (and 
thus the solvent) has to the tryptophan.  By measuring the kq, it is possible to quantify the 
efficiency of quenching and thus the amount of exposure of the tryptophan to solvent for 
direct comparisons between the various isoforms of the protein mutants. 
The purpose of quencher studies is to derive the rate that the quencher encounters 
the fluorophore due to dynamic quenching mechanisms. Acrylamide is the quencher we 
selected (Figure 3-4D) since it is a polar, non-ionic, electron-deficient molecule that can 
quench fluorophores in pockets or clefts of the protein matrix. Unlike ionic quenchers 
that may be hindered by electrostatics, acrylamide may be a better choice for fibrillar 
samples where the tryptophan may not be completely accessible at the surface.  
A problem frequently encountered while using acrylamide in determining the 
dynamic quenching rate constant in steady-state measurements is static quenching.  Static 
quenching occurs when the quencher forms a ground state complex with the fluorophore, 
causing a decrease in fluorescence as the excited-state electron immediately returns to the 
ground state without the emission of a photon [1].  This increases the observed Stern-
Volmer constant, but the data do not represent diffusion-controlled quenching 
mechanisms, which make it difficult to derive the true dynamic rate of quenching.  Stern-
Volmer plots representing both dynamic and static quenching mechanisms generally 
deviate from a straight line and display upward curvature as quencher concentration is 
increased.    
Multiple mathematical models have been derived to help give physical 
explanations to observations amidst the wide variation of tryptophan fluorescence data. 
65
Specifically for steady-state data, equations have been derived to try and separate the 
effects of static quenching from dynamic mechanisms [1, 5].  In a simple model, Eftink 
and Ghiron have reported a modified Stern-Volmer equation that tries to distinguish 
between static and dynamic quenching contributions in a Stern-Volmer plot displaying 
upward curvature [3].  This modified plot is represented by Equation 3-3.   
     F0/(Fexp(V[Q]))= 1+ KSV[Q]  Equation 3-3 
KSV is the dynamic quenching component and V is the static quenching component or the 
quenching “sphere of action” [3].  V has been described as representing the volume 
around the fluorophore where at the time of excitation, a quencher molecule is found and 
forms an encounter complex [5]. According to Eftink, V is related to the probability that 
the acrylamide is found close enough to the tryptophan as to quench it immediately or 
statically [3].  
It is important to note that although this modified Stern-Volmer equation gives a 
simple equation that attempts to distinguish between the contributions of static and 
dynamic quenching, and indeed can give some idea about the sphere of action of the 
tryptophan, it is ultimately applying a correction factor to the data to allow a fit to a 
straight line in plots displaying curvature in the slope.  It may not be a sufficient model 
when multiple or heterogenous populations of tryptophan molecules are present and each 
displays a unique static component.  
(B) Steady-State Quenching Results 
As seen in Figure 3-4(A-C), steady-state fluorescence was measured at increasing 
acrylamide additions.  For N159W, PrPC fluorescence is quenched at lower acrylamide 
concentrations than the PrPβ or PrPF isoforms. 
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Figure 3-4 (A-C). Representative steady-state quenching spectra for N159W in PrPC, 
PrPβ, and PrPF isoforms showing intensity vs. wavelength. Acrylamide was added at 0.05 
M increments up to 0.5 M concentration total. Overlayed quenching spectra for the other 
mutants in the three isoforms can be found in the Appendix (Figure A-2). (D) The 
structure of acrylamide. 
 
As seen in Figure 3-5, there is an upward curvature in the unmodified Stern-
Volmer plots (Equation 3-2), indicating combined static and dynamic quenching 
mechanisms. By plotting the data according to the modified Stern-Volmer equation 
(Equation 3-3), the contribution of the static component (represented by V) can be 
accounted for and the dynamic quenching rate constant estimated.  
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Figure 3-5 (A-F). Steady-state Stern-Volmer plots for Prpβ▲, PrPF ▲, and PrPC ▲ 
plotted according to modified and unmodified equations. When plotting the data to the 
unmodified Stern-Volmer equation (dotted lines) the left y-axis is used and when the data 
is plotted to the modified Stern-Volmer equation (solid lines) the right y-axis is used.   
 
 
With the exception of Y218W and Y163W PrPC, all the mutants in the various 
isoforms exhibit some amount of upward curvature and using the modified equation at 
least modestly improves the R2 values for the slopes.  Table 3-2 summarizes the slopes or 
KSV values using both unmodified and modified Stern-Volmer equations. When using the 
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modified Stern-Volmer equation, KSV represents the dynamic quenching constant and V 
represents the static quenching constant as determined by plotting the data to the 
modified Stern-Volmer equation and varying V until an optimum R2 value was achieved. 
In the case where V=0, no fit improvement could be attained and the data were left 
unmodified. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
71
 
 
Unmodified 
 
Modified 
 
Mutant & 
Isoform 
 
KSV (M-1) 
  
R2 
 
KSV (M-1) 
  
V (M-1) 
   
R2 
 
G123W  
14.5 ± 2.0 0.9947 11.9 ± 0.7 0.35 0.9979 PrPC 
PrPβ 4.7 ± 1.7 0.9845 4.1 ± 0.7 0.2 0.9989 
PrPF 4.9 ± 1.5 0.9912 3.5 ± 0.4 0.1 0.9946 
      
W145  
10.8 ± 1.6 0.9914 8.4 ± 0.8 0.4 0.9966 PrPC 
PrPβ 4.5 ± 0.7 0.9909 3.1 ± 0.8 0.5 0.9958 
PrPF 3.3 ± 0.1 0.9881 2.4 ± 1.2 0.4 0.9904 
      
Y150W 
5.2 ± 0.6 0.9975 4.1 ± 0.3 0.35 0.9999 PrPC 
PrPβ 3.7 ± 0.3 0.9928 2.2 ± 0.2 0.6 0.9977 
PrPF 4.1 ± 0.2 0.9909 3.2 ± 0.9 0.3 0.9930 
      
N159W  
17.4 ± 0.5 0.9898 11.3 ± 0.7 0.8 0.9993 PrPC 
PrPβ 4.4 ± 0.6 0.9946 3.4 ± 0.1 0.35 0.9968 
PrPF 3.7 ± 0.5 0.9953 2.6 ± 0.1 0.4 0.9977 
      
Y163W  
2.3 ± 0.1 0.9964 -------- 0 ------- PrPC 
PrPβ 5.1 ± 0.1 0.9962 3.6 ± 0.1 0.5 0.9994 
PrPF 5.7 ± 0.8 0.9833 3.4 ± 0.2 0.7 0.9913 
      
Y218W 
3.1 ± 0.7 0.9978 ------- 0 ------- PrPC 
PrPβ 5.1 ± 0.2 0.9964 4.1 ± 0.6 0.3 0.9982 
PrPF 4.4 ± 0.1 0.9895 3.5 ± 0.1 0.3 0.9918 
 
 
 
Table 3-2. The KSV values, V values, and fits to a straight line given by R2 for both 
modified and unmodified Stern-Volmer equations for the six mutants in the three 
isoforms. For the modified equation, KSV and V correspond to the Stern-Volmer constant 
for the dynamic component and the static quenching component, respectively. 
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When representing dynamic quenching, KSV-1 is the quencher concentration at 
which 50% of the intensity is quenched. For PrPC isoforms of mutants N159W, G123W, 
and W145, half the fluorescence is quenched below 0.15 M acrylamide whereas isoforms 
of the rest of the mutants require at least 0.25 M acrylamide to quench 50% of the 
fluorescence.   
 The static quenching constant is sometimes used to gain information on the 
exposure and surroundings of the tryptophan.  It was shown that in most single-Trp 
proteins there is a general agreement between V values and accessibility as determined 
by kq values [3].  Because the structure for PrPC is known and solvent accessible surface 
area (SASA) data can be calculated, it is interesting to examine the data more closely for 
this isoform. It is seen from Table 3-2 that N159W exhibits the largest V value while 
G123W, W145 and Y150W display lower yet significant V values and Y218W and 
Y163W do not improve with the fitting of any V component. The presence of a static 
component indicates that the quencher molecule can exist close enough to the indole ring 
to form a complex and statically quench the fluorescence.  While most of the V values for 
the various positions make sense in considering their corresponding SASA (Table 3-3), a 
couple exceptions exist.  
 Y163W, Y218W and Y150W all exhibit low Ksv values, have blue-shifted steady-
state intensity emissions (Table 3-1) and are predicted to have a low degree of solvent 
exposure from MOLMOL calculations (Table 3-3). As these positions are found within 
secondary structural elements of PrPC (see chapter 4) these data make sense. In the case 
of Y150W, however, the V value would argue that there is a significant amount of 
quencher accommodation at this position, even though it is part of α-helix 1, to allow for 
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complex formation with the quencher.  Similar discrepancies are observed for N159W.  
From Table 3-3, it can be seen that SASA for N159W is calculated to be 23% exposure, 
but the Ksv and the large V values along with the red shifted λmax (Table 3-1) are 
indicative of a much more exposed residue. Together, these data show that the probability 
of finding an acrylamide molecule adjacent to the tryptophan at position 159 is very 
favorable. The greater-than-expected solvent exposure may be due to intrinsic protein 
breathability at this position or to the presence and orientation of the tryptophan 
molecule, which could lead to quencher accommodation unpredicted by MOLMOL 
calculations.      
 
Mutant 
PrPC 
MOLMOL  
% exposure 
G123W 68 
    W145 46 
Y150W              4 
N159W 22 
Y163W              5 
Y218W 10 
 
Table 3-3.  SASA data for all six positions in PrPC calculated using the structure of 
PrP109-219 [PDB 1B10 [6] structure # 4 [7]] and MOLMOL software [4] by residue (see 
Methods, Chapter 2).  
 
 For PrPβ and PrPF isoforms, it is seen that every position exhibits at least some 
amount of static quenching.  While the KSV values show decreased exposure upon 
conversion, the existence of static quenching means that acrylamide can at least partially 
penetrate the multimeric complexes and exist adjacent to the fluorophore. For G123W, 
there is little static component compared to the other positions, so this N-terminal residue 
is not as free to complex with acrylamide in the β-rich isoforms.  For Y163W PrPF and 
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Y150W PrPβ slightly larger values for V are observed, indicating that acrylamide might 
readily bind within the active volume of the fluorophore.  
3-3. Time-Resolved Measurements 
 
(A) Introduction to Time-Resolved Measurements 
 
 While steady-state data can provide useful information on the environment of a 
fluorophore, much more sensitive information can be gained by the use of time-resolved 
fluorescence measurements. Time-resolved measurements are taken by exciting a sample 
with a pulse of light shorter than the decay time (lifetime) of the sample.  Lifetime is 
defined as the average time the molecules remain in the excited state following excitation 
[1] and is related to the rates of radiative decay (fluorescence) and non-radiative decay 
(nonfluorescence due to nearby quenching molecules: solvent, nearby polar residues, 
etc…[2]) given by Equation 3 – 4.  
τ = 1/(kr +knr)     Equation 3-4 
The lifetime is calculated by fitting the emission spectra to  
I(t) = I0e-t/τ     Equation 3-5 
for a single lifetime decay or  
I(t)= ∑αi exp (-t/τi)    Equation 3-6 
for multiple lifetime decays. α is the amplitude and represents the fraction of the 
molecules in each conformation, i, at t=0 [1].  Whereas the α values represent the 
amplitudes of the corresponding lifetimes to the intensity of the time-resolved data, the 
fractional contribution of each lifetime to the steady-state intensity is represented by 
Equation 3-7.  
f = αiτi/ ∑αiτi     Equation 3-7 
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Average lifetimes are often used in data interpretation and are represented by weighted 
(wtd) τ0, which gives the weighted average of all the lifetime components by Equation 3-
8. 
 <τ> =∑ αιτi2/ ∑ αiτI   Equation 3-8 
It has been proposed that single tryptophan proteins exhibit complex decays due 
to the presence of individual rotamers (rotation of the tryptophan moiety) within the 
protein.  If a single tryptophan can adopt slightly different rotamer configurations within 
the protein, then the indole ring will be exposed to slightly differing environments and 
interactions with nearby substituents or solvent, leading to different decay times for each 
rotamer [2, 8]. Movements or flexibility within the protein itself may also cause different 
microenvironments for the trytophan to encounter. In the fibrils and perhaps the β-
oligomer, multiple decay times could be indicative of either multiple rotamers within a 
monomer or of heterogenous populations within multi-subunit complexes.   
Fluorescence kinetics are complex and fitting is not always straight-forward. 
Because of the high complexity and variability of protein fluorescence, some suggest that 
the kinetics should not be described by discrete lifetime components, but should be 
represented by a distribution of lifetimes or a nonexponential decay [1, 8].  This requires 
fitting to additional models like Gaussian or Lorentzian distributions.  Although these 
fittings were not conducted for these data, the various methods of data analysis and 
potential mathematical models to describe physical phenomena should be considered 
when interpreting the data. 
Besides providing a more sensitive indicator of tryptophan environment, the 
emission lifetime (τ0) is needed to calculate the kq. The emission decay or lifetime is 
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proportional to the steady-state intensity.  The steady-state intensity at a given 
wavelength is the integral of the intensity decay at that wavelength;  
 
ISS= ∫I0e-t/τ dt = I0τ     Equation 3 -9 
 
The steady-state spectrum is then the sum of all the photons emitted during the lifetime 
decay over all the wavelengths of emission.  Figure 3-6 shows fluorescence emission 
decay as a function of time and wavelength to visibly demonstrate the connection 
between lifetime and steady-state emission.  
 
Figure 3-6. 3-D graph showing fluorescence intensity as a function of time and energy 
for 2,6-p-toluidinonapththalene adsorbed to egg L-α-lecithin vesicles.  The steady
spectrum is represented by the intensities at time=0 ns across all the wavelengths
multiplied by
-state 
 
 τ  (given by Equation 3-9). From Badea and Brand [9], used with 
ermission.  
 
 
p
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(B) Lifetime Results  
As described in the methods, the lifetime was measured for all the mutants in 
three isoforms; Equation 3-6  was convoluted with the instrument response function 
(IRF) and the resulting function was fit to the data using χ2 and  least square analysis.  
Weighted residuals were also obtained to observe the quality of fit. Values giving the 
lowest χ2 value and random weighted residuals were desired, but unless a significant 
improvement in χ2 (reduction by half) was shown, the simplest fit was 
the 
used. An example 
of fit and weighted residuals is shown for Y218W PrPβ in Figure 3-7. 
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igure 3-7. The fluorescence intensity decay fit to two lifetimes for Y218W PrPβ. (A) 
hows the weighted residuals for the calculated fit.     
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Table 3-4 summarizes the fluorescence decay parameters obtained for the mutants 
in the three isoforms. Most of the mutants in the various isoforms fit to multi-expon
decays with the short lifetime exhibiting the larger α values (normalized to unity). 
Whereas the short lifetime populations contribute more to the lifetime intensity as 
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indicated by the dominant amplitude value (Table 3-4), the contributions of each lif
component/population to the steady-state fluorescence intensity are almost evenly 
weighted
etime 
 (50/50 or 60/40) for the long and the short lifetime components as seen by the f-
α  τ  α  τ  <τ> f  f  
values.   
 
Mutant & 
Isoform 
 
 
1 1 2 2 1 2
 
G123W 
PrPC 0.41 ± 0.04 5.5 ± 0.1 0.59 ± 0.04 2.4 ± 0.1 4.3 ± 0.1 0.64 0.36 
PrPβ 0.26 ± 0.10 6.0 ± 0.4 0.74 ± 0.10 2.3 ± 0.1 4.2 ± 0.2 0.48 0.52 
PrPF 0.27 ± 0.03 4.6 ± 0.3 0.73 ± 0.03 1.3 ± 0.2 3.2 ± 0.3 0.56 0.44 
        
W145 
PrPC 0.20 ± 0.20 4.4 ± 0.1 0.8 ± 0.02 1.1 ± 0.1 2.7 ± 0.1 0.49 0.51 
PrPβ 0.22 ± 0.20 5.1 ± 0.4 0.78 ± 0.02 1.4 ± 0.2 3.3 ± 0.3 0.48 0.52 
PrPF 0.22 ± 0.02 4.8 ± 0.1 0.78 ± 0.02 1.2 ± 0.1 3.2 ± 0.2 0.55 0.45 
        
Y150W 
----  --  -- -  PrPC 1 4.4 ---------- ------- ------ ------- --------
PrPβ 0.2  6.5  0.8  2.6  4.1  0.4 0.6 
PrPF 0.31  5.5  0.69  1.7  3.9  0.58 0.42 
        
N159W 
PrPC 0.48 ± 0.23 6.6 ± 1.0 0.52 ± 0.02 2.7 ± 0.7 5.3 ± 0.2 0.65 0.35 
PrPβ 0.26 ± 0.02 5.3 ± 0.5 0.74 ± 0.02 1.7 ± 0.5 3.5 ± 0.4 0.51 0.49 
PrPF 0.26 ± 0.02 5.5 ± 0.1 0.74 ± 0.02 1.7 ± 0.1 3.7 ± 0.1 0.53 0.47 
        
Y163W 
PrPC 0.13  3.9  0.87  1.1  2.1  0.34 0.66 
PrPβ 0.29  5.0  0.71  1.4  3.6  0.6 0.4 
PrPF 0.29 ± 0.01 5.0 ± 0.1 0.71 ± 0.01 1.3 ± 0.1 3.6 ± 0.1 0.61 0.39 
        
Y218W 
0.98 ± 0.01PrPC 0.11 ± 0.03 3.8 ± 0.1 0.89 ± 0.03 1.9 ± 0.2 0.32 0.68 
PrPβ 0.21 ± 0.01 5.1 ± 0.1 0.79 ± 0.01 1.7 ± 0.1 3.2 ± 0.1 0.45 0.55 
PrPF 0.18 ± 0.03 4.4 ± 0.3 0.82 ± 0.03 1.2 ± 0.1 2.6 ± 0.2 0.44 0.56 
  
Table 3-4. Fluorescence decay parameters for the mutants in the different isoforms.   
 fractional contribution and α= amplitude of the corresponding lifetimes normalized to 
nity. <
 
f=
u τ>= weighted lifetime. Standard deviations represent replicated data. 
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 If considering the data according to the rotamer model of tryptophan lifetimes, 
one population of tryptophan may be near a quenching moiety such as a charged amino 
acid or solvent molecule giving it a shorter lifetime and another rotamer with a larger 
lifetime could indicate partial shielding or rotation away from the quenching moiety. It
seen that these populations generally c
 is 
ontribute similarly to the steady-state intensity 
while the shorter lif tensity as seen etime population contributes more to the lifetime in
from the f and α values, respectively. 
3-4. Time-Resolved Quenching Measurements 
(A) Introduction to Time-Resolved Quenching Measurements 
 As described in the steady-state sections, combined static and dynamic quenchin
can contribute significantly to the derivation of a diffusion-controlled quenching rate 
constant (kq).  Knowing which mathematical model represents the physical behavio
the system is also not straightforward.  Because time-resolved measurements take in
account only the emitting lifetime and not the statically quenched complexes, it is 
possible to derive a purely dynamic rate constant from a Stern-Volmer plot of time-
resolved quenching
g 
r of 
to 
 data. This bypasses the necessity of additional fitting procedures to 
separat
ta. This 
y a 
e mixtures of dynamic and static quenching components from steady-state 
quenching curves. 
 Just as τ0 can be fit to a distribution of lifetimes (exhibit non-exponential decay), 
it has been shown that the addition of quencher can produce a transient effect in 
diffusional quenching for some systems, contributing significantly to the decay da
transient effect complicates the decay order by making an initially exponential deca
nonexponential decay as quencher concentration is increased. In the presence of 
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quencher, a fluorophore population can give a non-exponential decay due to rapid 
quenching of closely spaced fluorophore and quencher molecules [1].   This deviates 
from the simple Stern-Volmer relationship, and while this transient term may or may
be involved in this particular syste
 not 
m, the influence of acrylamide on the fluorescence 
ider, as our data were only fit to discrete 
lifetime
properties of a protein is something to cons
s and not a distribution.    
(B) Time-Resolved Quenching Results   
Time-resolved measurements were taken as acrylamide was added in 0.05 M 
increments to a final concentration of 0.5 M, as for steady-state quenching.  α values 
were allowed to vary in the fitting procedures.  Stern-Volmer plots for the long, sh
weighted lifetimes were
ort and 
 plotted along with the amplitudes normalized to unity; Figure 3-
8(A-C) represents lifetime Stern-Volmer plots. Additional plots are shown in the 
appendix (Figure A-3). 
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Figure 3-8 (A-C). Time-resolved quenching Stern-Volmer plots and α values for 
Y218W PrPC, PrPβ, and PrPF.  
 
 
In PrPC, it was observed that for the mutants Y163W and W145 the lifetime 
Stern-Volmer plots have an unreasonable non-linear appearance for both the short and the 
long lifetime components as quencher is increased (see Appendix). In the others, the long 
component is preferentially quenched, as judged by the significantly steeper KSV values 
and the disappearance of the long lifetime component. Moreover, the ratio of amplitudes 
for each component varies as a function of acrylamide concentration. This indicates that 
independent dynamic quenching of each component is not occurring as should be 
expected.  This behavior has been suggested as being due to selective, static quenching of 
the long lifetime component [10]. For the PrPβ and PrPF samples the amplitudes remained 
constant and the long and short components display independent quenching behavior.  
Because the ratio of the amplitudes varied for PrPC as quencher was increased, 
data were plotted up to acrylamide concentrations where little amplitude deviation had 
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started to occur and KSV values were determined from these concentrations only.  Table 
3-5 shows Stern-Volmer constants and R2 values for weighted τ0 Stern-Volmer plots 
along with the highest concentration of acrylamide used for each plot before the α ratio 
values significantly varied. 
 
  Highest  
 
Mutant/Isoform  Ksv 
 
[Acrylamide] 
(M) 
 
R2 
 
G123W PrPC 9.6 0.2 0.999 
PrPβ 1.7 0.3 0.971 
PrPF 0.9 0.3 0.958 
    
W145 PrPC 9.7 0.15 0.981 
PrPβ 1.3 0.3 0.987 
PrPF 1.2 0.3 0.931 
    
Y150W PrPC 3.1 0.3 0.998 
PrPβ 1.7 0.3 0.989 
PrPF 1.0 0.3 0.993 
    
N159W PrPC 9.8 0.15 0.999 
PrPβ 1.5 0.2 0.987 
PrPF 1.1 0.3 0.991 
    
Y163W PrPC 2.4 0.3 0.972 
PrPβ 1.7 0.3 0.992 
PrPF 1.2 0.25 0.994 
    
Y218W PrPC 3.4 0.3 .969 
PrPβ 2.3 0.3 0.986 
PrPF 1.2 0.3 0.985 
 
Table 3-5. Stern-Volmer constants along with R2 values for the weighted τ0 plots to the 
acrylamide concentration indicated for each mutant and isoform.  
 
 
For N159W and W145 in the PrPC isoform, the long lifetime component was 
entirely quenched by 0.2 M quencher concentration and only one lifetime was then 
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observed. For some of the other samples, deviation of the α ratios occurred at higher 
quencher concentrations, so the Stern-Volmer constants could be determined usinghigher 
quencher concentrations.  For PrPF and PrPβ where the α ratios did not significantly 
deviate even out to 0.5 M acrylamide, KSV values were only taken to 0.3 M acrylamide 
for consistency. 
3-5. Solvent Accessibility (kq) Determination 
 (A) Introduction  
The final step in determining the solvent accessibility of the tryptophan residue is 
to use the KSV values from the time-resolved and steady-state Stern-Volmer plots and 
calculate the kq’s.  As mentioned earlier, the bimolecular quenching rate constant defines 
the dynamic rate of quenching over the lifetime of the fluorophore. Whereas time-
resolved quenching measurements report only the dynamic quenching component, 
steady-state quenching can become complicated with the mechanism of static quenching 
and may require mathematical modeling to acquire the dynamic component.  
(B) Results/Discussion 
The kq values for lifetime quenching (including the individual lifetime 
components) as well as steady-state quenching are summarized in Table 3-6.     
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Mutant & Isoform 
<τ> 
Wtd  
 
 τ1 
Long 
 
τ2 
Short  
 
Steady-State 
 
G123W PrPC 2.23 ± 0.23 2.06±0.68 3.06 ±1.72 2.58 ± 0.11 
PrPβ 0.37 ± 0.03 0.15 ± 0.01 0.89 ± 0.01 1.1 ± 0.10 
PrPF  0.29 ± 0.04 0.13 ± 0.01 0.43 ± 0.6 1.07 ± 0.16 
     
W145 PrPC 3.52 ± 0.75 1.68 ± 1.26 1.77 ± 0.62 3.17 ± 0.17 
PrPβ 0.42 ± 0.06 0.15 ± 0.01 0.61 ± 0.10 1.10 ± 0.22 
PrPF 0.39 ± 0.04 0.17 ± 0.02 0.66 ± 0.07 0.95 ± 0.10 
     
Y150W PrPC 0.7 --------- ------------ 0.90 ± 0.10 
PrPβ 0.42 0.17 0.58 0.60 ± 0.03 
PrPF 0.25 0.13 0.63 0.95 ± 0.13 
     
N159W PrPC 1.85 ± 0.09 1.88 ± 0.55 2.6 ± 2.3 2.06 ± 0.07 
PrPβ 0.41 ± 0.11 0.21 ± 0.09 0.68 ± 0.26 0.86 ± 0.08 
PrPF 0.29 0.15 0.75 0.83 ± 0.04 
     
Y163W PrPC 1.15 0.25 0.97 1.12 ± 0.05 
PrPβ 0.48 0.2 0.63 1.12 ± 0.01 
PrPF 0.35 ± 0.09 0.18 ±0.04 0.71  ±0.34 1.28 ± 0.01 
     
Y218W PrPC 1.83 ± 0.04 1.56 ± 0.14 1.32 ± 0.37 1.68 ± 0.15 
PrPβ 0.71 ± 0.03 0.29 ± 0.01 0.95 ± 0.11 1.42 ± 0.19 
PrPF 0.47  ±0.08 0.23 ± 0.04 1.34 ± 0.23 1.37 
 
kq values 
(X 109 M-1s-1) 
Table 3-6. Rate constants for each lifetime component (weighted, long and short) along 
with steady-state kq values. Steady-state kq values were calculated using the modified 
Stern-Volmer plot while taking the lifetime determined for the sample used for steady-
state measurements. Standard deviations represent replicated data. Stern-Volmer 
constants (steady-state and time-resolved) were determined from the slopes plotted out to 
the same quencher concentration for each mutant and isoform.  See Table 3-5 for 
appropriate acrylamide concentrations used in KSV determination for each mutant and 
isoform. 
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It can be seen from Table 3-6 that for all mutants, the  PrPβ and PrPF isoforms 
have weighted kq values that fall in between the kq values for the long and short lifetime 
components, while most all of the mutants in the PrPC isoform do not follow that pattern. 
This is explained mathematically by the changing α ratios in PrPC when fitting the data to 
a multiexponential decay at increasing quencher concentrations. Although the individual 
components do not behave in a manner consistent with independent dynamic quenching 
as observed from the changing amplitude ratios, the weighted lifetime Stern-Volmer plot 
does follow expected, linear behavior and the kq’s obtained from the weighted lifetime 
<τ0> are similar to the kq’s derived from the modified steady-state Stern-Volmer plot.   
In contrast to PrPC, the misfolded isoforms are similar and maintain relatively 
constant α ratios. This indicates that each lifetime behaves as an independent component 
expressing individual Stern-Volmer constants. While weighted lifetime kq’s do fall 
between the kq’s for the short and long lifetime components, they are not similar nor do 
they directly correlate with the kq’s derived from steady-state quenching, unlike the PrPC 
isoform.  This suggests that the modified Stern-Volmer equation used to correct for the 
static quenching does not sufficiently explain the physical behavior of the tryptophan 
steady-state quenching for these two isoforms. Because these two forms are made of 
multiple subunits, the tryptophan could be in heterogeneous (different monomers having 
different environments) and/or pocketed environments and other models may be 
necessary to explain the differences observed between steady-state and lifetime 
quenching kq’s [1, 5]. More complex mathematical models of quenching exist [5] and 
further fitting could potentially separate the components of static from dynamic 
quenching or perhaps supply a better physical interpretation of the steady-state data.  
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Normally they accomplish the goal of quantifying the accessibility of a tryptophan by 
determining the kq value representing diffusion-controlled quenching mechanisms, but 
they could be difficult to assess in the absence of a known structure. With the use of the 
time-resolved measurements, the requirement for more complex mathematical fitting for 
steady-state data becomes unnecessary.  
Using the kq determined from the weighted τ0  as representative of the overall 
tryptophan accessibility, it can be seen that the tryptophan becomes less accessible in the 
PrPβ and PrPF isoforms for all the mutants and that the G123W, W145 and N159W 
mutants show the greatest change in kq values between PrPC and the misfolded isoforms. 
 As seen in the steady-state section, kq values show a strong correlation to λmax 
values.  Just as the λmax values become more homogenous in PrPβ and PrPF isoforms, the 
weighted-τ0 kq values exhibit a similar, smaller range of values compared to the variation 
observed in PrPC. 
 It has also been seen throughout all the sections that PrPβ and PrPF exhibit similar 
fluorescence characteristics from steady-state spectra to lifetimes, KSV values and kq’s. 
This lends support for using PrPβ as a model for the PrPF isoform.  
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CHAPTER 4: DISCUSSION/CONCLUSIONS 
 
The goal of my research was to observe changes in accessibility of tryptophan 
residues at specific positions that occur upon misfolding of the prion protein. By 
determining tryptophan accessibility changes among isoforms, positions exhibiting 
significant conformational changes can be identified, theoretical models of PrPSc can be 
assessed, and gathered data can be compared with structural data obtained from other 
reported techniques. Accessibility was determined by tryptophan fluorescence quenching 
measurements whereby the rate of dynamic quenching (kq) and thus the solvent 
accessibility of the tryptophan could be measured and quantified.  This chapter starts with 
a discussion of the data obtained from the results section and explains why particular kq 
values are used to represent accessibility in each isoform. The kq values are then used in 
conjunction with MOLMOL data to correlate kq’s with solvent accessible surface area in 
PrPC and provide an estimate of tryptophan accessibilities in the misfolded isoforms. The 
accessibility data are then examined in context of structural information and are related to 
the computational models of PrPSc along with data from other techniques as discussed in 
the introduction. This chapter concludes with future directions.  
4-1. kq Determination from Dynamic Quenching 
 As seen in the results chapter, the kq derived from steady-state measurements can 
be strongly influenced by static quenching mechanisms.  Most mutants in the various 
isoforms exhibited at least some upward curvature in the steady-state Stern-Volmer plots, 
indicating static quenching was occurring, particularly at high quencher concentrations. 
While a modified Stern-Volmer equation may attempt to mathematically separate static 
and dynamic quenching components, the use of time-resolved quenching measurements 
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circumvents this need, as statically quenched complexes do not emit.  In addition, using 
the modified Stern-Volmer equation appropriately accounts for the static quenching 
components in the PrPC isoforms as the weighted time-resolved kq values are comparable 
to kq values acquired with the steady-state modified Stern-Volmer equation as seen in 
Table 3-6.  For PrPβ and PrPF, however, the kq’s derived from weighted time-resolved 
measurements are much lower than the kq values acquired from the steady-state modified 
Stern-Volmer equation.  This may indicate that the simple modified Stern-Volmer 
equation does not sufficiently separate the static and dynamic quenching components. 
Because the misfolded isoforms are multimeric complexes, there will be multiple 
tryptophan residues and environments per complex and each may exhibit both unique 
dynamic and static quenching components. Different environments in the misfolded 
monomers, especially significant at the ends versus the center of the fibril, can lead to 
unique static (V) and dynamic (KSV) values for each tryptophan complicating the 
estimation of the overall static component in a simple modified Stern-Volmer fit of 
steady-state data. Although it may be possible to further use complex fitting methods and 
find an appropriate mathematical model to separate these components, the use of time-
resolved quenching bypasses all static components and allows for the derivation of purely 
dynamic quenching rate constants.  
 Lifetime measurements can exhibit multi-exponential decay rates suggesting the 
presence of either different tryptophan rotational conformations (rotamers) of the same 
Trp or different populations. In the case of the misfolded, multimeric isoforms, it is 
logical to assume there may be more than one population of tryptophan in the multimeric 
molecule. While the analysis of lifetime measurements still prove very difficult in 
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distinguishing the individual accessibilities of each tryptophan population in the protein 
(due to numerous possibilities of local environment effects and self quenching), weighted 
lifetimes, however, provide an average accessibility of the tryptophans in the molecule, 
giving an overall depiction of the average accessibility of the tryptophan.  Using kq’s that 
represent the dynamic rate constant of the overall population of the tryptophan (derived 
from the weighted lifetime Stern-Volmer plots), it is possible to compare accessibilities 
and overall changes of each tryptophan mutant upon conversion to a different isoform. 
For the following sections of data discussion, kq values for PrPC will be taken from the 
steady-state modified Stern-Volmer plots to compare with other steady-state data from 
literature. Since the steady-state and lifetime kq values for PrPC are within experimental 
error, the kq values for PrPβ and PrPF will be taken from the weighted lifetime Stern-
Volmer plots since the steady-state measurements cannot be modified to acquire a true 
dynamic component.  
4-2. Correlating kq’s with Tryptophan Solvent Accessible Surface Area (SASA) 
As kq is a measurement of the solvent accessibility of the fluorescing molecule, it 
should be possible to correlate kq with the exposure of the tryptophan in a known 
structure. One program used by our lab to determine solvent accessible surface area 
(SASA) is MOLMOL [1]. Although this program was used to calculate the percent 
exposure of the entire residue (including backbone) and not just the side chain, it can give 
information on the tryptophan accessibility to solvent. In a paper published by Eftink and 
Ghiron, steady-state quenching measurements were conducted with proteins containing 
single tryptophan residues and the kq values were reported [2].  At the time of the study, 
structures for all the proteins were not available.  However, structures of many of these 
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proteins are now deposited in the protein data bank. I therefore determined the SASA of 
the tryptophan residues in the proteins using MOLMOL.  For these proteins, the 
experimentally determined kq values were plotted vs. the percent exposure of the 
tryptophans, and a linear correlation was observed (Figure 4-1). This correlation could be 
compared to the data obtained from the kq’s and SASA of tryptophan in PrPC, as the 
NMR structure of PrPC has been determined. Using the NMR structure of PrPC, a 
particular residue was mutated to tryptophan using Sybyl (see Methods), and each 
individual mutated structure was energy minimized. These structural representations of 
PrPC containing single tryptophan residues were used for SASA determination.  The 
correlation of tryptophan SASA and kq values can be further used to theoretically 
estimate the percent accessibility of the tryptophan in the misfolded isoforms of PrPβ and 
PrPF. 
 
 
 
 
 
 
 
Figure 4-1. Graph fitting correlation of SASA and kq values for single-tryptophan 
containing proteins with previously measured kq values (blue diamonds) comparing fit 
with PrPC mutants (pink squares) along with the theoretical values of SASA  of 
PrPβ (yellow triangles) and PrPF (green circles). Eftink proteins represented are glucagon 
(59% exposed, PDB file 1GCN), monellin (35%, PDB file 1IV9), Human Serum 
Albumin (HSA) (20%, PDB file 2BXG), S. Nuclease (18%, PDB file 1EY0), and Rnase 
T1 (1%, PDB file 1IYY) 
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Mutant 
PrPC 
MOLMOL 
% exposure 
PrPβ 
Theoretical 
% exposure
PrPF 
Theoretical 
% exposure
kq  
(x109 M-1s-1) 
kq 
(x109 M-1s-1)
kq 
(x109 M-1s-1) 
G123W  2.58 ± 0.11 68 0.37 6 0.29 5 
W145  3.17 ± 0.17 46 0.42 7 0.39 7 
Y150W  0.90 ± 0.10 4 0.42 7 0.25 4 
N159W  2.06 ± 0.07 22 0.41 7 0.29 5 
Y163W  1.12 ± 0.05 5 0.48 8 0.35 6 
Y218W  1.68 ± 0.15 10 0.71 12 0.47 8 
Table 4-1. Measured kq values of tryptophan in the various mutants and isoforms. The 
percent exposures of the tryptophan in PrPC was determined by MOLMOL calculations 
from the NMR structure of ShaPrP109-228 [PDB 1B10 [3] structure # 4 [4]] whereas the 
percent exposures of PrPβ and PrPF were calculated using slope of Figure 4-1. 
 
 
 
 
PrPC 
 
PrPβ 
 
PrPF 
 
 λmax  
(nm) 
 
Intensity
 
λmax 
(nm) 
 
Intensity
 
λmax 
(nm) 
 
Intensity
 
G123W 353  0.28 347  0.27 339  0.4 
  W145 351  0.10 347 0.17 344  0.21 
Y150W 336  0.62 344  0.21 343  0.29 
N159W 352  0.38 344  0.23 343  0.18 
Y163W 336  0.06 345  0.17 343 0.22 
Y218W 334  0.04 348  0.12 343  0.18 
 
Mutants 
Table 4-2. (same as Table 3-1) Representative λmax and intensity values from the steady-
state spectra of the six mutants in the three isoforms. All intensities are normalized to 20 
μM concentration. 
 
(A) PrPC 
The percent solvent accessible surface area (SASA) of tryptophan residues in 
single-Trp proteins were graphed as a function of their kq values (Figure 4-1) determined 
by Eftink [2]. While small indole derivatives and free Trp in solution approach the 
diffusion limit and have kq values between 7-10 x 109 M-1s-1, the maximum values 
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expected for exposed residues in a randomly coiled or unstructured dynamic peptide 
attached to a backbone will be smaller and are represented by glucagon (Figure 4-1) and 
ACTH (not shown) as measured by Eftink, having kq values of 3.7 and 4.2 x 109 M-1s-1, 
respectively. Since glucagon is an intrinsically dynamic peptide, NMR and X-ray 
structures have been elucidated only when the molecule is interacting with a lipid or 
receptor. So, the calculated SASA is based on a structure of glucagon that may not 
maximally represent the exposure of this residue in a completely unstructured peptide. 
However, even when exhibiting secondary structure in the form of an α-helix, glucagon’s 
Trp is highly exposed (~60%) and shows good correlation with the rest of the data in 
Figure 4-1.  Table 4-1 shows the kq values for positions in PrPC calculated using steady-
state data and modified Stern-Volmer plots.  It is noteworthy to add that the steady-state 
and weighted lifetime kq values of PrPC did not give significantly different results, and 
the steady-state values were used to compare to the kq values of other proteins given in 
literature by steady-state data.  The tryptophan positions in PrPC exhibit a wide range of 
SASA, from highly exposed in W145 to significantly buried in Y150W.  It is also seen 
from the results (Table 4-2 replicating Table 3-1) that the measured λmax values of the 
steady-state spectra of PrPC mutants correlate well with the range and extent of solvent 
accessibility. The residues in PrPC exhibiting the greatest accessibility as seen from 
SASA and kq values are W145 and G123W; these have the most red-shifted spectra. 
The slight correlative deviation of PrPC mutants from Eftink proteins could also 
be explained by different experimental conditions. It can be seen in Figure 4-1 that PrPC  
kq’s, taken apart from the other single-Trp proteins, demonstrate a close correlation with 
predicted SASA. The kq values for other single-Trp proteins studied by Eftink were all 
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measured by the same laboratory, just as PrPC mutant kq values were all measured under 
similar experimental conditions. While showing some deviation from the correlation of 
other single-Trp proteins, the correlations among PrPC mutants would make sense if 
experimental conditions were a factor.    
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Figure 4-2. Showing PrP109-219.  For visualization purposes, all six tryptophan 
mutations were inserted together and the resulting structure was energy minimized. This 
differs from the method used to calculate individual tryptophan SASA values listed in 
Table 4-1.  Accessibility based on kq values is represented by color from red (most 
accessible) to blue (least accessible); red>orange>yellow>green>blue. 
 
While the solvent accessibility calculations for G123W and W145 indicate fully 
exposed residues (compare to glucagon), G123W has a much lower kq value than 
expected for a fully exposed residue. At first glance (Figure 4-2) it appears peculiar that 
G123W reports less accessibility in kq values than W145, as it is located in such a floppy 
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segment of protein and appears to have more solvent accessibility according to 
MOLMOL calculations. One explanation for this behavior is that G123W is located in 
the hydrophobic segment of prion known to exhibit transient structure in wild type PrPC 
[5]. It is postulated that this hydrophobic segment is slightly stabilized by interaction with 
Helix B or the first β-strand (S1) as has been suggested from NMR data [5]. The 
formation of this transient interaction would only be furthered favored and stabilized by 
the presence of a hydrophobic tryptophan residue.  This propensity could account for the 
lower-than-expected kq value for G123W.     
In contrast to G123W, all the rest of the positions (except W145) exhibit higher kq 
values than the SASA data would indicate (Figure 4-1; note that this structure is truncated 
missing the last 12 residues of Helix C). This discrepancy may be due to some flexibility 
of PrPC in solution. The protein in the monomeric form is flexible, especially in the 
unstructured N-terminus (residues 90-119).  In fact it is seen that all tryptophan positions 
with the exception of Y150W display multiple decay components (Table 3-3), which is 
indicative of single tryptophan residues sampling multiple environments, different local 
quenching effects, and thus multiple lifetime decays. From our data, it can be argued that 
there exists some flexibility at the positions tested allowing for rotational conformations.  
Also, the existence of a static quenching component for every position except Y218W 
and Y163W (Table 3-2) would indicate that the structure is accommodating enough even 
in buried areas of well-defined secondary structure (Y150 in Helix A) to allow for 
complex formation between the tryptophan and the quencher. N159W shows a very large 
static quenching component in contrast to its relatively low SASA. This may indicate a 
favorable accommodation of the quencher, either through intrinsic flexibility of the 
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protein, or due to the presence and orientation of the Trp residue having greater exposure 
than predicted by MOLMOL.   
 In the case of Y218W, the residue appears to be much more exposed than 
predicted from its structure. This phenomenon was also observed in tyrosine nitration 
studies where Y218 was more reactive to nitration than predicted based on the 
MOLMOL solvent accessibility calculations [6]. A potential explanation in the tyrosine 
nitration study was that conformational changes induced by nitration of other nearby 
residues (Tyr 225 and Tyr 226) allowed for increased accessibility of Tyr 218. In 
addition, there are other factors that influence tyrosine nitration besides solvent 
accessibility (see YYR epitope section starting on page 18). The introduction of a 
tryptophan residue could have potentially caused a local change in structure that was not 
well accounted for in the energy-minimized Y218W model used for SASA 
determination, causing it to be more accessible than predicted by MOLMOL. However, 
taken together, the tyrosine nitration and tryptophan fluorescence data could indicate the 
presence of a solvent accessible pocket or flexibility within the globular domain, which 
remains unobserved in the NMR data. 
(B) PrPβ 
  Eftink reported kq values of single-Trp proteins based on steady-state fluorescence 
quenching and the calculated SASA was used to create Figure 4-1. It was shown that kq’s 
measured for PrPC using steady-state fluorescence quenching coupled with SASA 
correlate well with the plot. Table 3-6 shows that steady-state and time-resolved kq values 
for PrPC provide very comparable data. Therefore, time-resolved kq data for PrPβ and 
PrPF can be used to predict the theoretical solvent accessibility of the overall tryptophan 
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molecules. This kq data would indicate that all six residues become more buried upon 
conversion to PrPβ and have solvent accessibilities in a narrow range of  ~6-11%.       
  For PrPβ, we used the weighted lifetime Stern-Volmer plot to determine kq, and 
the SASA/kq correlation plot (Figure 4-1) to determine the overall accessibility of the 
tryptophan residues in PrPβ.  Overall, it is seen that there is a decrease in solvent 
accessibility at every tryptophan position after conversion to the misfolded isoform. 
While it may not be possible with a very large aggregated molecule to determine whether 
these decreases in solvent accessibility are due to conformational change within 
monomers or inter-subunit packing events, PrPβ is only an octamer [6, 7]. Therefore, if a 
conformational change occurs that increases the accessibility of a Trp molecule, it should 
be possible to detect using quenching techniques. It was seen through intrinsic 
fluorescence in alpha-synuclein peptide that while the exposed Trp residue became 
buried upon conversion to the fibril, it stayed exposed in the oligomeric intermediate 
forms [8]. This provides evidence that tryptophan fluorescence quenching can be used to 
evaluate exposure in multimeric complexes, especially in oligomers. Therefore, our data 
suggest that all six positions in PrP are more buried in PrPβ than in PrPC.  However, the 
largest changes in SASA are noted for W145 and G123W.   
 Also seen from the Table 4-1 and Figure 4-1, the kq values for all the mutants in 
the PrPβ isoform cluster and are around 0.4-0.5 x 109 M-1s-1. These similar values are 
supported by consistent λmax values from steady-state spectra within PrPβ indicating 
similar solvent exposures (Table 4-2).  
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(C) PrPF 
Much like the PrPβ isoform, PrP fibrils exhibit a clustering of kq values in the 
range 0.3-0.4 x 109 M-1s-1, and this observation is also supported by the narrow range of 
blue shifted λmax values in the steady-state spectra (Table 4-2). Again, while the 
discrimination between conformational change or packing effects may not be straight-
forward, it can be seen that the kq values of PrPβ are always slightly greater than the kq 
values of PrPF, and this could be plausibly attributed to the greater packing (less solvent 
exposure) in fibrils than in the octameric β-oligomer.  
The range in theoretical solvent accessibilities, as predicted using kq values, is 
similar to that of PrPβ and spans from ~4-8% with Y218W being the most accessible. For 
a relative comparison concerning the accessibility of the residues in the misfolded 
conformations, the accessibility of Y150W can be examined. The exposure of position 
Y150W in PrPC is very similar to the accessibility of positions in PrPβ and PrPF as it 
exhibits a kq value of 0.7 x 109 M-1s-1 (weighted τ), 0.9 x 109 M-1s-1 (steady-state)  and a 
solvent exposure of 4%. This can be compared to the kq values in the misfolded isoforms 
ranging from ~0.3-0.7 x 109 M-1s-1. Thus, position 150 does not appear to undergo any 
large change in solvent exposure upon conversion to a β-enriched isoform.  
Although there is an observable trend toward hydrophobic and buried 
environments in PrPβ and PrPF, when positions are considered individually as a function 
of conformation, a clearer picture emerges. G123W and W145 both exhibit a very large 
change from highly exposed to significantly buried in both misfolded conformations 
(Table 3-6). Also, the static quenching component (V) decreases in G123W upon 
conversion (Table 3-2). These observed changes imply that the N-terminus (at least 
101
residues 90-145) takes on alternative structure and that the residues become highly buried 
and may be part of the hydrophobic core.  This is also seen in N159W, although to a 
lesser extent.  N159W in PrPC is on the cusp of the second β-strand (161-163) and while 
it is seen to be fairly exposed based on kq calculations (Table 3-6), it may form at least 
some transient extended β-structure [5].  Upon conversion to PrPSc, N159W is seen to 
significantly decrease its solvent accessibility, potentially becoming part of the 
hydrophobic β-sheet core. The residues at positions 150, 163 and 218 are all included in 
well defined α-helical (150, 218) or β-strand (163) secondary structure. Upon 
conversion, their solvent accessibilities decrease, but the changes in exposure are small 
compared with the other three mutants. While structural changes could be occurring at 
these positions, it is not possible from this data to distinguish between structural changes 
in the monomer and inter-subunit packing causing the decrease in accessibility.   
 Our laboratory as well as others have used PrPβ as a representative isoform of 
PrPSc due to its solubility for spectroscopic analysis. Because of this, it is noteworthy to 
add that data from both PrPF and PrPβ  were very comparable and exhibited 
commonalities throughout the results.  Similar patterns and ranges in steady-state spectra, 
lifetimes, quenching profiles and kq values all provide significant support for the 
suitability of the β-oligomer for depicting the structures of the fibrillar samples. 
4-3. Computational Models of PrPSc 
 
A hypothesis of my thesis was that both the β-helix and β-spiral model are 
mutually exclusive and by probing conformational differences among the isoforms using 
Trp fluorescence and quenching, these models could be distinguished, supported or 
challenged. This section examines the two computational models of PrPSc, the predictions 
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of accessibility of residues based on these structures, along with the quenching data and 
its implications. 
(Α) β−Helix Model 
 
 
159 
218 
163  
150  
123  145  
B.   
 
 
 
 
 
 
 
 
 
 
A.  
Figure 4-3. Showing Govaerts model for PrPSc [9]. (A) shows a trimer of misfolded 
residues comprising the fibillar core. (B) shows a close-up of a single monomer and the 
six mutant positions used in this study. Residues are colored similarly to Figure 4.2: 
(From most to least exposed in PrPC based on kq calculations): W145 ■ G123 ■  N159 ■  
Y218 ■  Y163 ■   Y150 ■. Structure coordinates kindly provided by Govaerts. 
 
 
In the β-helix model by Govaerts [9], residues 89-175 form β-helices while the C-
terminal alpha helices B and C remain mostly intact along with the disulfide bridge. β-
strands forming parallel β-sheets can wrap around in a helical fashion creating a supra 
secondary structure known as the β-helix. The β-helical conformation allows for 
stackable trimeric units interacting at the tops and bottoms of the β-helices to form cross 
β-structure parallel to the long fibril axis [9].   
It is possible to look more closely at the residue positions within the β-helix 
model (Figure 4-3) to compare with the kq derived accessibility data.  In-silico mutations 
and energy minimizations on the computational trimeric model were not performed due 
to the instability of the model during the energy minimization process. SASA data were 
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therefore collected on the native residues at those positions to obtain an idea of the 
exposure of the side chain. While not very obvious in Figure 4-3, W145 is located on the 
top rung of the β-helix and could form contacts with the bottom rung of an additional β-
helix trimer stacked on top, which is the model for fibrillar formation. W145 would 
therefore be buried, which is consistent with our quenching data. G123W is found within 
the β-sheet core of the helix and is not very solvent exposed, which is also consistent 
with the quenching data. In contrast, N159W is on the kink of the turn and is very highly 
exposed to solvent, which is not compatible with the low kq measured in our studies.  
Y150, Y163, and Y218 all fell in the range of ~40-50% exposure, and it does not appear 
that trimer stacking would cause these residues to become buried from solvent when part 
of the fibrillar complex; this is not consistent with the respective quenching data 
predicting solvent exposures for these residues between 7-12% in PrPβ.  Therefore, even 
when trimer stacking is considered, the SASA estimations of the β-helix model do not fit 
with the solvent accessibility data derived from our kq determinations.  
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(Β) β-Spiral Model 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-4. Shows simulation of conversion from PrPC to the β-spiral model of PrPSc (a) 
with the α-helices labeled HA, HB, HC and the β-strands labeled S1 and S2 in PrPC and 
E1-E4 (for extended structure) in PrPSc. (b) shows the hydrogen bonds between the β-
strands in PrPC and the β-strands or extended structure in PrPSc following conversion. 
Figure taken from [10], copyright 2004 National Academy of Sciences, U.S.A. 
 
The β-spiral model [10-12] is based on the formation of extended β−strand 
structure in the N-terminal region. Although there are two short β-strands in PrPC (Figure 
4-4b), this model predicts that PrPSc contains an increase in β-sheet extended structure 
with the formation of additional β-strands (residues 116-132 and 160-164).  In contrast 
with the β-helix model, the structure of helix A is largely unchanged. Though the 
increased β-sheet structure in the N-terminal region is similar to the β-helix model, there 
are some major differences between the two models.  In contrast to the β-helix model, 
there is no stacking of the cross-β structure, but rather the spiraling of extending sheets 
formed by both parallel and antiparallel extended β-strands. Strikingly, residue 123 is 
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positioned at the turn between E1 and E2 and is highly accessible, in contrast to the β-
helix model where G123 is buried within the β-helical structures. To provide further 
information in the hopes of distinguishing between the two proposed models of PrPSc, 
Valerie Daggett and Mari DeMarco, who developed the β-spiral model, calculated SASA 
of various residues using their own methods [13].  Solvent exposure at specific residues 
was compared between the two models and positions were chosen that exhibited the 
largest changes in SASA, and so could most easily distinguish among PrPC and the two 
models of PrPSc. 
  
Summary Solvent Exposure 
    PrPC Spiral Beta-helix 
GLY 123 exposed  Exposed (76) buried      (6) 
TRP 145 exposed  Exposed (89) buried     (15) 
ASN 159 buried  buried    (12) exposed (120) 
 
Table 4-3. Shows positions and their corresponding calculated solvent accessible surface 
area data (SASA) in the β-spiral model and the β-helix model of misfolded PrP. 
Calculated SASA was provided by Mari DeMarco and Valerie Daggett using their own 
methods. The SASA data are not recorded as percentages.   
 
 
 In the β-spiral model, both G123 and W145 should be highly exposed, which is 
not consistent with the quenching data.  Quenching data for N159W, however, is 
consistent with the β-spiral model as this position is predicted to be buried.  In contrast, 
the β-helix model shows residue 123 and 145 as being part of the β-helices and buried, 
but N159W is on the corner of a loop and will be very solvent accessible.  In both 
models, Y218W is found to still be part of the α-helix with not much conformational 
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change. The decrease in kq value upon conversion to a β-enriched isoform may be 
attributed to the protofibrillar packing in the β-spiral or in the β-helix model the stacking 
of trimers and/or the packing of protofibrils. Y218W, although still more buried than in 
PrPC, had the greatest kq/solvent accessibility of all the mutants. This seems reasonable 
according to both of these models.  Based on the combined SASA calculations (Table 4-
3) and the observable locations of the Trp residues in both models (Figures 4-3 and 4-4), 
it is seen that the accessibility data derived from the kq values (Table 4-1) do not fit well 
with either computational model.   
4-4. Experimental Techniques and Related Structural Data 
(A) YYR Epitopes 
While residues 123, 145, and 159 were chosen because they were predicted to 
distinguish between the β-helix and β-spiral models of PrPSc, residues 150, 163, and 218 
were chosen for slightly different reasons. Although these three residues have the 
potential to distinguish between the theoretical models, other studies using antibodies and 
tyrosine nitration prompted the study of these positions. Y218W is located in the most C-
terminal α-helix and doesn’t show much change in either model. Because of this, it was 
originally considered a good “control” position, although its susceptibility to nitration [6] 
might suggest otherwise.  Residues 150 and 163 are tyrosines found within the two YYR 
motifs in PrP (residues 149-151 and 162-164). Work done by Cashman and colleagues 
[14] found that there is increased accessibility of one or both of the YYR motifs in PrPSc 
compared to PrPC. Specifically, it was reported that antibody binding targeting the YYR 
epitope occurs in PrPSc but not in PrPC, suggesting that at least one of these repeats 
becomes more surface exposed in the misfolded state.  More recently, the YYR epitope 
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containing Y150W was found to become more sensitive to tyrosine nitration following 
conversion to PrPβ  [6].  In this report, both Y163W and Y150W were designed to 
investigate the two YYR motifs. It was expected that at least one of these mutants 
(probably Y150W) would exhibit a large increase in solvent accessibility upon 
conversion.  However, neither mutant displayed any increase in kq in either PrPβ or PrPF; 
in fact both positions showed a slight decrease in accessibility. These seemingly 
contrasting results may imply that the other tyrosine in the YYR repeat is the residue 
responsible for this observed increase in nitratability. This requires closer examination of 
the various methods involved in accessibility determination for further interpretation.  
In the YYR epitope binding study, monoclonal anti-YYR antibodies were used in 
immunoprecipitation reactions to characterize the specificity for binding PrPSc over PrPC. 
It was found that monoclonal YYR antibodies immunoprecipitate PrPSc but do not select 
for PrPC. In addition, binding of soluble antigen Tyr-Tyr-Arg to the monoclonal 
antibodies inhibited their plate binding in an ELISA assay. While soluble antigen Tyr-
Ala-Arg showed competitive binding, soluble Ala-Ala-Ala antigen did not show any 
inhibition [14]. These data could indicate that access to the N-terminal tyrosine or the C-
terminal arginine of YYR may be more important than the central tyrosine in binding the 
antibody, lending support to the hypothesis that tyrosine 149 or 162 would be the more 
accessible residue.    
Concerning the tyrosine nitration studies, it can be seen from the mass 
spectrometry data that the YYR epitope encompassing residues 149-151 became more 
readily nitrated upon conversion to PrPβ. Upon closer examination, it was also seen that 
residue 150 was capable of becoming nitrated, but the main nitrotyrosine species detected 
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in PrPβ was at position 149 [6]. Additionally, there are factors other than solvent 
exposure that significantly influence tyrosine nitration, potentially influencing the results 
[15]. It is possible that the presence of nearby charged residues would influence the 
preference to nitrate Y149. Nearby positively charged or sterically hindering residues 
near a tyrosine will decrease its propensity to react with a nitrating reagent. Since Y150 is 
adjacent to R151, it is possible that Y149 is less hindered and more able to undergo 
nitration. Conversely, nearby negatively charged residues will positively influence 
tyrosine nitration. All in all, there are factors in addition to solvent exposure that 
determine the ability of a tyrosine to react with nitrating reagents and closer scrutiny of 
the mechanisms involved provide support for tyrosine 149 as being the residue that is 
preferentially nitrated. It is also possible that the presence of a more hydrophobic 
tryptophan molecule in the place of tyrosine would change the structure and reduce this 
position’s solvent exposure, as the fraction of tryptophans found buried at least 95% in 
proteins exceeds that fraction found for tyrosine residues [15].   Even though Y150 and 
Y149 are adjacent, it is possible to imagine structures, a simple β-strand being one of 
them, whereby one residue is buried (facing inwards) and one is facing out towards 
solvent and is more prone to be nitrated or bind to antibodies.  
(B) H/D Exchange, EPR and the Surewicz Model 
While both β-helix and β-spiral models were derived through computational 
methods and map the hydrophobic, β-sheet core of PrPSc to the N-terminal region (up to 
residue 175 in the β-helix model), experimental studies have been conducted that provide 
evidence for a different region comprising this β-sheet core of PrPSc. Mass spectrometry 
work by Surewicz using hydrogen/deuterium exchange techniques mapped the cross β-
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structural core to residues 169-213, as these residues were most highly protected from 
exchange. The rapid exchange noted for N-terminal residues 90-140 indicates that this 
portion of PrP is void of an extensive, stable, hydrophobic backbone structure like a β-
sheet stacking interaction [16]. However, when looking at the H/D exchange data for the 
monomeric PrPC, it can be seen that while some of the segments containing α-helices are 
measurably protected, considerable exchange still takes place over the course of 1-2 
hours and some α-helical and β-sheet segments exhibit exchange times and deuterium 
incorporation resembling the fibril exchange data for regions existing outside the β-sheet 
core (169-213) [16]. This argues that secondary structure outside the highly protected 
region (169-213) may exist in the form of α-helices or simple β-strands/sheets although 
not involved in the stacking, cross-β sheet core.  
Very recent studies by this group using EPR and spin labeling implicated the 
presence of parallel, in-register β-strands comprising a cross-β structural core spanning 
residues ~160-220. These results were seen even after forming fibrils under 
physiologically relevant, non-denaturing conditions at low pH [17]. Again, residues 
outside of this site were not seen to possess tight packing or the high degree of order 
required for single-line spectra spin exchange, but this does not rule out structural 
organization in the N-terminus (residues ~90-160) as most of these positions did exhibit 
dipolar broadening [18].  In light of this information (which was not available at the 
beginning of our experimental design) and the stark contrast with the other two 
computational models, we therefore sought to compare the Surewicz model with our 
fluorescence data. The Surewicz studies support the decrease in accessibility of residues 
159, 163 and 218. Positions 159, 163, and 218 would be located within the cross-β 
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structure that has been shown to possess in-register, parallel stacking of β-strands of the 
individual misfolded monomers.  Studies involving prions from yeast [19] and other 
amyloidogenic peptide fragments including prion have provided evidence of a “steric 
zipper” structure where one parallel cross β-strand packs adjacent to another parallel 
cross β-strand forming a dry, hydrophobic, tightly-formed zipper that shields the residues 
within the core from solvent [20].  If this were the case, tryptophans at 159, 163, and 218 
would be found within the hydrophobic zipper structure, be stacked in-register and be 
highly buried from solvent. This would agree with the SASA data acquired from our kq 
values. It is not possible to determine the SASA of the N-terminus using the Surewicz 
data and so positions 123, 145 and 150 cannot be fully evaluated in context with this 
model. However, it is plausible that the residues outside the parallel β-sheet core exhibit 
some secondary structure, and may become more buried upon conversion. It has been 
shown through FTIR data that there is a significant increase in β-structure upon 
conversion of PrPC to PrPSc, but only a slight decrease in α-helicity has been observed 
[12]. Because of this, it is plausible that conversion of the N-terminus could occur to 
form α-helical secondary structure.  
(C)  Antibody Binding 
 Epitope mapping studies have been performed among the various prion isoforms 
and can be used as a tool to provide information concerning regions of a protein sequence 
that bind with an antibody and are thus near the surface. Using the YYR epitope 
experiments combined with nitration data, it may be possible to elucidate the individual 
residue accessibilities. However from most other epitope studies, it is not possible to 
distinguish between accessibilities of individual residues as the antibodies may target 
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discontinuous or conformational epitopes in the protein. Typical epitopes are 4-6 residues 
at a minimum. In this respect, it may not be possible to compare the kq accessibility 
results of a single residue with antibody studies in which the epitope recognized includes 
at least 5 residues. While attempting to find positions that report similar or increased 
solvent accessibility upon conversion, PrPSc-selective epitopes provide potential positions 
that undergo a change of accessibility and/or are near the surface.  There are only a few 
PrPSc specific antibodies that have been found, one of which is the YYR epitope 
discussed previously. Another, I5B3, is a discontinuous epitope comprising residues 142-
148, 162-170, and 214-226 [21]. These residues are accessible in the β-spiral model but 
do not fit the β-helix model [12]. The Surewicz model has the potential to fit the I5B3 
data as well, depending on how the N- and C-Termini pack together around the in-
register, stacking β-core protofibrils. Another PrPSc-selective antibody designated as IgG 
136-158 has been shown to bind a fraction of PrPF (23-230). This same antibody is 
shown to bind to a subfraction of PrPβ form as well, although to a lesser extent than PrPF  
[22].  Although these data show similar binding of PrPSc-selective antibodies to PrPF and 
PrPβ, there are some differences in conformation as this antibody only bound a fraction of 
the two isoforms. Nonetheless, it supports these regions as potentially containing 
accessible residues within the misfolded forms. Also, both these PrPSc selective 
antibodies fit the β-spiral model and may fit Surewicz model depending on tertiary 
conformation but conflict with the β-helix model as residues 136-158 are found within 
the center of the model [12].  
Another PrPSc-specific antibody is IgG 89-112, mapping to the N-terminus 
(residues 89-112) of PrP90-231 [22]. This antibody is found to bind PrPSc but not PrPC 
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and is shown to bind a fraction of PrPF as seen from fluorescence studies [22]. Binding of 
IgG 89-112 to PrPβ was minimal and resembled that of the PrPF fraction shown not to 
bind.   This demonstrates that conformational differences exist in the various misfolded 
isoforms.  D13 antibody recognizes residues 95-105, and binds to PrPF (23-231) [22] and 
to some extent in truncated PrPF (90-231) [7] but is less accessible in PrPSc (PrP27-30 - 
proteinase-K resistant core) [23]. Taken together, the data indicate that although there are 
slight conformational differences among the misfolded isoforms, there are N-terminal 
residues that remain or become more solvent exposed upon conversion.      
 The exposure of C-terminal epitopes has also been explored. While Novitskaya 
concluded that residues 224-230 in PrPF (23-230) were buried and resistant to 
denaturation [22], others have shown it to be accessible in PrPC as well as in PrPSc 
(PrP27-30) and PrPF (90-231) [7, 12, 23].    
To summarize, while antibody binding can map solvent accessible epitopes of a 
protein, discontinuous or conformational recognition along with the inherent “multi-
residue” nature of an antibody epitope makes it difficult to assess individual residue 
solvent accessibility within a given epitope. At all six of the positions tested here, no 
tryptophan becomes more accessible upon conversion to the misfolded form. By using 
antibody data, it becomes possible to predict regions that may remain or become 
accessible for binding upon conversion, and this information may be helpful in targeting 
new positions for future Trp quenching studies. 
4-5. Summary 
Weighted time-resolved kq values were used to determine the overall accessibility 
of the tryptophan mutants in the various isoforms. Because kq values derived for PrPC 
113
from both steady-state and time-resolved measurements were similar, and because of the 
presence of static quenching and multiple tryptophan residues in PrPβ and PrPF 
potentially exhibiting unique static and dynamic components, weighted time-resolved kq 
values were used to estimate the average Trp exposure in the misfolded isoforms.  Using 
these values, it was possible to correlate SASA with kq in PrPC and provide an estimate of 
the SASA of the Trp residues in PrPβ and PrPF.   Although SASA varied among Trp 
positions in PrPC, the predicted accessibilities of positions in PrPβ and PrPF were very 
similarly buried, clustering between 4-11% exposure. 
All residues examined were seen to become less accessible upon conversion to the 
misfolded forms, with the largest changes occurring in G123W and W145.  This could 
indicate that the N-terminal residues become more structured and/or form the 
hydrophobic core of the aggregates. While large accessibility changes were seen to occur 
at these residues and to a lesser extent at N159W, no residues that we examined were 
shown to stay as accessible or become more accessible in the misfolded forms. While 
there may be difficulties with measuring Trp fluorescence and quenching in aggregates, it 
has been shown that in the oligomeric intermediates of fibril formation with α-synuclein, 
the Trp residue stays exposed and becomes buried only upon formation of fibrils [8]. 
Therefore, it should be possible to find a position that shows increased or similar 
exposure in the misfolded conformers, at least in PrPβ. Therefore, if an appropriate 
residue were chosen, fluorescence quenching could be used to show a change in 
conformation leading to an increase in exposure. If identified, this position would be an 
ideal reporter of aggregate formation of the diseased state.  
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Tryptophan accessibilities were used to evaluate models of PrPSc and were also 
compared to data derived from other experimental techniques. It was found that neither 
computational model of PrPSc entirely fit our data.  We have sought to compare our data 
with that from the recent Surewicz model of parallel, in-register β-strands comprising 
residues ~160-220. Because this model is not complete and elicits no structural detail on 
residues outside this range, it is not possible to fully compare with our data.  However, 
for the residues falling within this area (163, 218 and 159), this model is supported by the 
decrease in solvent accessibility. 
With various pieces of experimental data, it is possible to further refine the 
conformational criteria for the misfolded isoforms eventually elucidating a structure. In 
the absence of experimental data, computational methods have been utilized to model the 
misfolded structure. With experimental methods like H/D exchange and site-directed 
spin-labeling (SDSL) EPR, structural information on larger segments or regions of 
proteins can be examined, while other techniques involve looking for changes in residue 
or epitope exposure among isoforms. Tryptophan fluorescence can give specific 
information concerning individual residues and can be used in conjunction with the other 
methods to give detailed accessibility information for further structural elucidation.  
4-6. Future Directions 
It was an initial aim of my project to identify a position that undergoes a large 
conformational change between the cellular and misfolded isoforms. This finding could 
lead to new detection assays using a reporter molecule at the position of the large change 
to indicate the misfolding of the prion, in conjunction with PMCA [24] or other 
techniques.  While significant changes in solvent accessibility have been observed among 
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the isoforms, none of the six positions examined was found to be more accessible in PrPβ 
or PrPF than PrPC. The identification of a residue that becomes solvent exposed only in 
the β-enriched isoforms would be potentially more useful and insightful, because of the 
potential for a reporter position recognizing conversion to the misfolded isoforms 
separate from any affects of fibril aggregation.  Future directions would be to mutate 
other positions to accomplish this.  A logical “next” experiment would investigate 
tryptophan fluorescence at residues 162 and 149, as one of these epitopes should be more 
exposed, based on tyrosine nitration [6] and antibody studies [14]. Because positions 150 
and 163 did not become more accessible, it is possible that the adjacent tyrosine is 
responsible for the increased accessibility noted in these studies.   
Also of interest would be the region between residues 90-105 and 225-230, as the 
antibody binding studies in this region have shown evidence that some residues remain 
exposed in PrPSc  [22, 23]. This also may provide further information concerning 
theoretical models, as both the β-helix and β-spiral model invoke the N-terminal region 
in the formation of β-sheets whereas data from Surewicz indicates that the C-terminal 
region between ~160-220 is primarily involved in β-sheet formation, not the N-terminus.    
A further step would be to use tryptophan screening and mutate every position 
along the protein deriving accessibility information for every residue. While this would 
be very illuminating, it may not be very practical due to the time it takes to make and 
purify each mutant protein, along with analyzing the time-resolved data. 
Although it should be possible to find a residue that shows increased accessibility 
between PrPC and the misfolded isoforms, tryptophan fluorescence quenching may not be 
the best method for structural determination based the problems inherent to the formation 
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of large aggregates. Overall, using a multitude of different techniques, including 
fluorescence, it is possible to examine various models of PrPSc as they become available.  
This would bring researchers one step closer to solving the structural mysteries of the 
misfolded prion protein.   
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Figure A-1.  Steady-state spectra for additional mutants in the three different isoforms 
PrPC,  PrPβ, and PrPF. All spectra normalized to 20 μM concentration.  
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Figures A-2 (I-V).  Steady-state quenching spectra for five mutants in (A) PrPC , (B) 
PrPβ, and (C) PrPF isoforms. Acrylamide was added at 0.05 M increments up to 0.5 M 
concentration total. 
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Figures A-3 (I-V): (A) column shows time-resolved quenching Stern-Volmer plots for 5 
mutants in PrPC, PrPβ, and PrPF. (B) column shows α values of the corresponding 
lifetime normalized to unity as a function of quencher concentration for 5 mutants in 
various isoforms.  
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